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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and
Allergies (NDA) derives dietary reference values (DRVs) for potassium. The Panel decides to set DRVs on
the basis of the relationships between potassium intake and blood pressure and stroke. The
Panel considers that randomised controlled trials and an observational cohort study carried out in a
European adult population provide evidence that a potassium intake of 3,500 mg (90 mmol)/day has
beneﬁcial effects on blood pressure in adults. Furthermore, there is consistent evidence from
observational cohort studies that potassium intakes below 3,500 mg/day are associated with a higher
risk of stroke. Available data cannot be used to determine the average requirement of potassium but can
be used as a basis for deriving an adequate intake (AI). A potassium intake of 3,500 mg/day is
considered adequate for the adult population and an AI of 3,500 mg/day for adult men and women is
proposed. For infants and children, the AIs are extrapolated from the AI for adults by isometric scaling
and including a growth factor. An AI of 750 mg (19 mmol)/day is set for infants aged 7–11 months. For
children, AIs from 800 mg (20 mmol)/day (1–3 years old) to 3,500 mg/day (15–17 years old) are set.
Considering that the daily accretion rate of potassium in fetal and maternal tissues can be met by the
adaptive changes which maintain potassium homeostasis during pregnancy, the AI set for adults applies
to pregnant women. For lactating women, the amount of potassium needed to compensate for the losses
of potassium through breast milk is estimated and an AI of 4,000 mg (102 mmol)/day is proposed.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a Scientiﬁc Opinion on Dietary Reference Values (DRVs) for
the European population, including potassium.
Potassium is an essential mineral in the human diet. It is the predominant osmotically active
element inside cells. It plays a major role in the distribution of water inside and outside cells, assists in
the regulation of the acid–base balance, and contributes to establishing a membrane potential which
supports electrical activity in nerve ﬁbres and muscle cells. Potassium has a role in cell metabolism,
participating in energy transduction, hormone secretion, and the regulation of protein and glycogen
synthesis.
Potassium is present in all natural foods, in particular starchy roots or tubers, vegetables, fruits,
whole grains, dairy products and coffee. Based on the data from 13 dietary surveys in nine countries
of the European Union, average potassium intakes ranged between 821 and 1,535 mg (21 and
39 mmol)/day in infants (< 1 year), between 1,516 and 2,005 mg (39 and 51 mmol)/day in children
aged 1 to < 3 years, between 1,668 and 2,750 mg (43 and 70 mmol)/day in children aged 3 to
< 10 years, between 2,093 and 3,712 mg (54 and 95 mmol)/day in children aged 10 to < 18 years,
and between 2,463 and 3,991 mg (63 and 102 mmol)/day in adults (≥ 18 years).
Potassium deﬁciency, presenting as hypokalaemia, is deﬁned as a serum potassium concentration
lower than 3.5 mmol/L and is usually caused by increased potassium losses (e.g. via diarrhoea,
vomiting or excessive renal losses) or intracellular shift of potassium (e.g. during alkalosis).
Hypokalaemia resulting from insufﬁcient dietary intake is rare and may be associated with severe
hypocaloric diets, or with a relative insufﬁciency caused by an increased requirement of potassium for
the synthesis of tissue during recovery from malnutrition.
About 90% of dietary potassium is absorbed, mainly in the small intestine. Body potassium content
is regulated by the balance between dietary intake and renal excretion. Urine is the major route of
potassium excretion, while the remaining part is eliminated in the faeces and, to a lesser extent, in the
sweat. Urinary potassium excretion, based on 24-h urine collection, is regarded as a reliable biomarker
of dietary intake in adults on a population basis.
Most of body potassium is located in the muscle, with lower amounts present in the bone, liver,
skin and red blood cells. Because of tight homeostatic mechanisms, blood potassium concentrations
and total body potassium content are only minimally affected by variations in dietary potassium intake.
The Panel therefore considers that there is no suitable biomarker of potassium status which can be
used for setting DRVs for potassium in the general population.
Potassium intake has been reported to be associated with several health outcomes, particularly
cardiovascular endpoints. Overall, the Panel considers that randomised controlled trials and an
observational cohort study carried out in a European adult population provide evidence that a
potassium intake of 3,500 mg (90 mmol)/day has beneﬁcial effects on blood pressure in adults.
Furthermore, there is consistent evidence from observational cohort studies that potassium intakes
below 3,500 mg (90 mmol)/day are associated with a higher risk of stroke. Evidence on the
association between potassium intake and coronary heart disease is unclear and inconsistent. Evidence
in relation to diabetes mellitus type 2, kidney stones and bone health were also reviewed but the
available data could not be used to derive DRVs for potassium.
The Panel decides to set DRVs for potassium based on the relationship between potassium intake
and blood pressure and stroke. Currently, available data cannot be used to determine the average
requirement of potassium but can be used as a basis for deriving an adequate intake (AI). A
potassium intake of 3,500 mg (90 mmol)/day can be considered adequate for the adult population and
an AI of 3,500 mg (90 mmol)/day for adult men and women is proposed.
No data are available on which to base an average potassium requirement for infants and children.
The Panel derives AIs extrapolated from the AI for adults, taking into account differences in reference
body weight (isometric scaling) and including a growth factor to take into account requirements for
growth. The AI set for infants aged 7–11 months is 750 mg (19 mmol)/day. For children, AIs range
from 800 mg (20 mmol)/day (1–3 years old) to 3,500 mg (90 mmol)/day (15–17 years old).
The Panel considers that the requirement for the daily accretion rate of potassium in fetal and
maternal tissues can be met by the adaptive changes which maintain potassium homeostasis during
pregnancy. The AI for pregnant women is set at 3,500 mg (90 mmol)/day, the same as for non-
pregnant women.
Dietary reference values for potassium
www.efsa.europa.eu/efsajournal 3 EFSA Journal 2016;14(10):4592
Considering evidence which indicates that total body potassium content decreases in lactating
women, a conservative approach is taken and the amount of potassium needed to compensate for the
losses of potassium through breast milk is added to the AI for adult. Thus, an AI of 4,000 mg
(102 mmol)/day is proposed for lactating women.
Dietary reference values for potassium
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Background as provided by the European Commission
The scientiﬁc advice on nutrient intakes is important as the basis of Community action in the ﬁeld
of nutrition, for example such advice has in the past been used as the basis of nutrition labelling. The
Scientiﬁc Committee for Food (SCF) report on nutrient and energy intakes for the European
Community dates from 1993. There is a need to review and, if necessary, to update these earlier
recommendations to ensure that the Community action in the area of nutrition is underpinned by the
latest scientiﬁc advice.
In 1993, the SCF adopted an opinion on the nutrient and energy intakes for the European
Community.1 The report provided Reference Intakes for energy, certain macronutrients and
micronutrients, but it did not include certain substances of physiological importance, for example
dietary ﬁbre.
Since then new scientiﬁc data have become available for some of the nutrients, and scientiﬁc
advisory bodies in many European Union (EU) Member States and in the United States have reported
on recommended dietary intakes. For a number of nutrients, these newly established (national)
recommendations differ from the reference intakes in the SCF (1993) report. Although there is
considerable consensus between these newly derived (national) recommendations, differing opinions
remain on some of the recommendations. Therefore, there is a need to review the existing EU
Reference Intakes in the light of new scientiﬁc evidence, and taking into account the more recently
reported national recommendations. There is also a need to include dietary components that were not
covered in the SCF opinion of 1993, such as dietary ﬁbre, and to consider whether it might be
appropriate to establish reference intakes for other (essential) substances with a physiological effect.
In this context, the European Food Safety Authority (EFSA) is requested to consider the existing
population reference intakes (PRIs) for energy, micro- and macronutrients and certain other dietary
components, to review and complete the SCF recommendations, in the light of new evidence, and in
addition advise on a PRI for dietary ﬁbre.
For communication of nutrition and healthy eating messages to the public, it is generally
more appropriate to express recommendations for the intake of individual nutrients or substances in
food-based terms. In this context, EFSA is asked to provide assistance on the translation of nutrient-
based recommendations for a healthy diet into food based recommendations intended for the
population as a whole.
Terms of reference as provided by the European Commission
In accordance with Article 29 (1)(a) and Article 31 of Regulation No 178/20022, the Commission
requests EFSA to review the existing advice of the Scientiﬁc Committee for Food on PRIs for energy,
nutrients and other substances with a nutritional or physiological effect in the context of a balanced diet
which, when part of an overall healthy lifestyle, contribute to good health through optimal nutrition.
In the ﬁrst instance, EFSA is asked to provide advice on energy, macronutrients and dietary ﬁbre.
Speciﬁcally advice is requested on the following dietary components:
• carbohydrates, including sugars;
• fats, including saturated fatty acids, polyunsaturated fatty acids and monounsaturated fatty
acids, trans fatty acids;
• protein;
• dietary ﬁbre.
Following on from the ﬁrst part of the task, EFSA is asked to advise on PRIs of micronutrients in
the diet and, if considered appropriate, other essential substances with a nutritional or physiological
effect in the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to
good health through optimal nutrition.
Finally, EFSA is asked to provide guidance on the translation of nutrient-based dietary advice into
guidance, intended for the European population as a whole, on the contribution of different foods or
categories of foods to an overall diet that would help to maintain good health through optimal
nutrition (food-based dietary guidelines).
1 Scientiﬁc Committee for Food, 1993. Nutrient and energy intakes for the European Community. Reports of the Scientiﬁc
Committee for Food, 31st series. Food – Science and Technique, European Commission, Luxembourg, 248 pp.
2 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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Assessment
1. Introduction
In 1993, the Scientiﬁc Committee for Food (SCF) adopted an opinion on nutrient and energy
intakes for the European Community. For potassium, the SCF proposed a population reference intake
(PRI) of 3,100 mg (80 mmol)/day for adults, including pregnancy and lactation, and a Lower
Threshold Intake of 1,600 mg (40 mmol)/day, which was accepted as the intake needed to avoid low
plasma potassium concentrations (SCF, 1993).
2. Deﬁnition/category
2.1. Chemistry
Potassium (K) is an abundant and highly reactive alkali metal which makes up 2.4 mass% of the
Earth’s crust. It has an atomic mass of 39.1 Da. Potassium is present in only one oxidation state (+ 1).
It is a powerful reducing agent that is easily oxidised. Because of its high reactivity, potassium is not
found free in nature but only as salts. Potassium compounds have good water solubility.
Naturally occurring potassium is composed of three isotopes, namely the stable isotopes 39K (natural
abundance 93.3%) and 41K (6.7%), and the radioactive isotope 40K (0.01%), which has a very long
half-life (1.251 9 109 years). The latter is responsible for most of the naturally occurring radioactivity in
the body (Kee et al., 2010; Crook, 2012).
2.2. Function of potassium
2.2.1. Biochemical functions
Potassium is an essential mineral in the human diet. Potassium is the predominant osmotically
active element inside cells. Together with sodium and chloride, which are characteristic of the
extracellular ﬂuid, potassium contributes to osmolarity and plays a major role in the distribution of
ﬂuids inside and outside cells. In addition, potassium participates in the regulation of the acid–base
balance. Differences in potassium and sodium concentrations across cell membranes are maintained by
the speciﬁc permeability of membranes to each of these ions and by Na+/K+-ATPase activity, which
pumps sodium out of and potassium into the cells (Bailey et al., 2014; Gumz et al., 2015). The enzyme
Na+/K+-ATPase plays an important role in the strict homeostatic control of plasma potassium
concentrations. As a result, the intracellular potassium concentration is about 30 times higher than that
of plasma and interstitial ﬂuid. This concentration gradient (largely responsible for driving the
membrane potential) is important for the transmission of electrical activity in nerve ﬁbres and muscle
cells. Small changes in the ratio of extracellular to intracellular potassium concentration have large
effects on neural transmission, muscle contraction and vascular tone (Bailey et al., 2014; Gumz et al.,
2015). Potassium transport across the membranes of the endothelial and vascular smooth muscle cells
has important effects on their contractile state, which can, in turn, inﬂuence endothelial function, blood
ﬂow and blood pressure (Haddy et al., 2006). The concentration of potassium in cells of the collecting
duct system of the kidney is important for the excretion of sodium. Maintenance of the
transmembrane gradient is the key element for electrolytes and ﬂuid homeostasis, a critical factor in
blood pressure regulation (Bailey et al., 2014; Gumz et al., 2015).
Passive transport of potassium occurs via intracellular and paracellular pathways. The intracellular
transport mechanism involves potassium channels. Channels have ‘gates’ which open or close in
response to speciﬁc stimuli, such as voltage, ATP, ionic calcium concentration, hormones and
neurotransmitters. Various stimuli sometimes act together on a channel. Potassium channels exhibit
great diversity and may be divided into four main groups: voltage-gated (Kv) channels; calcium-activated
(KCa) channels, covering big conductance (BK), intermediate conductance (IK), and small conductance
(SK) channels; inwardly rectifying (Kir) channels, and two-pore domain (K2P) channels (Heitzmann and
Warth, 2008; Horn et al., 2014). Different types of potassium channels have been implicated in functions
such as salivary secretion, bile and gastric acid secretion, protein digestion and absorption, insulin
secretion, carbohydrate digestion and absorption, and taste transduction.
Potassium has a role in cell metabolism, participating in energy transduction, hormone secretion
and the regulation of protein and glycogen synthesis. Potassium is a cofactor for a number of enzymes
Dietary reference values for potassium
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including glycerol dehydrogenase, mitochondrial pyruvate carboxylase, pyruvate kinase, L-threonine
dehydratase, ATPases and aminoacyl transferase (Page and Di Cera, 2006; Toraya et al., 2010).
2.2.2. Health consequences of deﬁciency and excess
2.2.2.1. Deﬁciency
Potassium deﬁciency, presenting as hypokalaemia, is deﬁned as a serum potassium concentration
lower than 3.5 mmol/L (Pepin and Shields, 2012). In general, deﬁciency may be caused by increased
potassium losses via diarrhoea, vomiting, burns or excessive renal losses (owing, for example, to renal
tubular acidosis, high secretion of mineralocorticoids, some diuretics) leading to low total body
potassium (Crop et al., 2007; Rodenburg et al., 2014). Hypokalaemia can also occur when total body
potassium is normal in case of an intracellular shift of potassium (Rastegar, 1990). The most important
causes of an intracellular shift include alkalosis, insulin excess, catecholamine excess and familial
periodic paralysis (i.e. a genetic disease related to malfunction in the ion channels in skeletal muscle
cell membranes) (Gumz et al., 2015). Hypokalaemia resulting from insufﬁcient dietary intake is rare
and may be associated with severe hypocaloric diets or occur as the result of an increased
requirement needed for the synthesis of new tissue (e.g. muscle) during recovery from malnutrition.
Hypokalaemia is generally associated with increased morbidity and mortality, especially from cardiac
arrhythmias or sudden cardiac death. When serum potassium concentration is < 3 mmol/L, the
prevalence of malignant ventricular arrhythmia has been observed to increase twofold in patients on
diuretic treatment (Byatt et al., 1990). The risk of atrial ﬁbrillation is higher in hypokalaemic subjects
compared to the general population (Krijthe et al., 2013). Other adverse consequences of
hypokalaemia include polyuria, muscle weakness, decreased peristalsis possibly leading to intestinal
ileus, mental depression and respiratory paralysis in severe cases (Rodenburg et al., 2014).
2.2.2.2. Excess
Hyperkalaemia is commonly deﬁned as a serum potassium concentration greater than
approximately 5.5 mmol/L in adults (Pepin and Shields, 2012; Michel et al., 2015). Hyperkalaemia is
often asymptomatic and diagnosed because of conduction abnormalities on the electrocardiogram
(Lehnhardt and Kemper, 2011). Clinical manifestations of mild to moderate hyperkalaemia are usually
non-speciﬁc and may include generalised weakness, paralysis, nausea, vomiting and diarrhoea (Pepin
and Shields, 2012). Severe hyperkalaemia may lead to life-threatening cardiac arrhythmias (Paice
et al., 1983; Lehnhardt and Kemper, 2011).
Hyperkalaemia is rare in the general population. The majority of cases occur from impaired renal
function (Lehnhardt and Kemper, 2011; Crook, 2012). Non-renal causes include inappropriately high
intakes of oral potassium supplements or parenteral potassium administration and a potassium shift
from cells (for instance in the case of metabolic acidosis, hypoxia, severe tissue damage).
Hyperkalaemia following excessive dietary intake of potassium is rare because of the effective
homeostasis mediated by increased cellular uptake of potassium from the bloodstream by various
organs and increased urinary excretion (Lehnhardt and Kemper, 2011).
No tolerable upper intake level (UL) has been set for potassium by EFSA due to insufﬁcient data
(EFSA, 2005). The Panel considered that the risk of adverse effects from potassium intake from food
sources (up to 5,000–6,000 mg (129–154 mmol)/day in adults) is low for the general healthy population.
It also stated that long-term intakes of about 3,000 mg (77 mmol) potassium/day as potassium chloride
supplements, in addition to intake from food, have been shown not to have adverse effects in healthy
adults (Cappuccio et al., 2016). A few case studies have reported that supplemental potassium in doses
of 5,000–7,000 mg (128–179 mmol)/day can cause adverse effects on heart function in apparently
healthy adults. Gastrointestinal symptoms have been observed in healthy subjects taking some forms of
potassium supplements (e.g. slow release, wax-matrix formulations) with potassium doses ranging from
about 1,000 to 5,000 mg (26–128 mmol)/day, but incidence and severity seem to depend more on the
formulation than on the dose (EFSA, 2005).
2.3. Physiology and metabolism
2.3.1. Intestinal absorption
About 90% of dietary potassium is absorbed, mainly in the small intestine, mostly through passive
mechanisms in response to electrochemical gradients (Agarwal et al., 1994; Bailey et al., 2014).
Dietary reference values for potassium
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In the proximal small intestine, water absorption provides a driving force for the movement (solute
drag) of potassium across the intestinal mucosa. In the ileum, the transepithelial electrical potential
difference strongly inﬂuences its movement. It has been hypothesised that potassium may also be
actively absorbed in the small intestine due to the presence of an H+/K+-ATPase in the apical membrane
(Heitzmann and Warth, 2008). In surface cells of the distal colon, potassium is excreted through apical
potassium channels in exchange for sodium which is reabsorbed through epithelial sodium channels.
Potassium may also be reabsorbed in the colon through the action of luminal H+/K+-ATPases (colonic
type), which can be of importance during potassium deprivation (Meneton et al., 1998).
2.3.2. Transport in blood
In healthy individuals, serum potassium concentrations range between 3.5 and 5.5 mmol/L,
whereas plasma concentrations are lower by about 0.3–0.4 mmol/L. This difference is due to a release
of potassium during clot formation (Nijsten et al., 1991; Sevastos et al., 2008). Homeostatic
mechanisms act to maintain blood potassium concentration within a narrow range, even in the
presence of wide variations in dietary potassium intake (Giebisch, 1998, 2004; Palmer, 2014; Gumz
et al., 2015) (Section 2.3.3).
In plasma, most potassium is present as free ions and 10–20% is bound to proteins (Ifudu et al.,
1992).
2.3.3. Distribution to tissues
Around 98% of systemic potassium is within the cells, making potassium the major intracellular
cation. Most of body potassium is located in the muscle (70%), with lower amounts present in the
bone, liver, skin and red blood cells (Weiner et al., 2010). Most of the body potassium (about 85%) is
rapidly exchangeable (half time of less than 7 h), while exchanges with red blood cells and brain pools
are slower (Jasani and Edmonds, 1971).
Intra- and extracellular concentrations of potassium are maintained within narrow limits. After a meal,
potassium is absorbed and rapidly enters the extracellular ﬂuid. The subsequent rise in plasma potassium
concentration is quickly attenuated by cellular uptake (Giebisch, 1998; Palmer, 2014). Na+/K+-ATPase is
responsible for the active transport of potassium into the cells and for the maintenance of the extra- and
intracellular sodium and potassium concentrations against electrochemical gradients. This ATPase is
found in the cytoplasmic membrane of virtually all cells (McDonough and Nguyen, 2012). Potassium is
also actively transported into some gastrointestinal cells and renal tubules by H+/K+-ATPase
(Sections 2.3.1 and 2.3.5.1). Various Na+-K+-Cl cotransporters, which carry Na+, K+ and Cl into the
cell and are driven by the force of ion gradients, have been identiﬁed in the salivary glands,
gastrointestinal tract and renal tubules (Sections 2.3.1 and 2.3.5.1). The K+-Cl cotransporter plays an
important role for erythrocytes to maintain a speciﬁc shape and mediates potassium efﬂux (Lote, 2007).
Potassium transfer between the extra- and intracellular milieus is inﬂuenced by a variety of
endogenous and exogenous factors (Gumz et al., 2015). Cellular potassium uptake by the muscle,
liver, bone and red blood cells is promoted by the increase in plasma potassium concentration, by
insulin, epinephrine and aldosterone, by metabolic alkalosis, and by drugs activating b-2 adrenergic
receptors. Conversely, a decrease in plasma potassium concentration, metabolic acidosis,
hyperosmolarity of the extracellular ﬂuid, and a-antagonist drugs induce potassium transport from cells
to the extracellular ﬂuid. Hyperkalaemia stimulates the secretion of insulin, aldosterone and
epinephrine, while hypokalaemia has the opposite effect (Giebisch, 2004; Grossman et al., 2013).
The mechanisms of fetoplacental potassium transfer have not been fully elucidated. Animal studies
indicate that potassium is actively transported across the placenta and that the developing fetus is
efﬁcient in maintaining constant potassium concentration in plasma (Atkinson et al., 2006; Lorenz,
2012). Fetal potassium content was observed to be maintained in case of maternal potassium
restriction (Lorenz, 2012). In a cross-sectional study on 344 healthy pregnant women, potassium
concentrations in both fetal and maternal plasma did not differ with gestational age (15–38 weeks of
gestation), at 3.5–3.6 mmol/L in the fetuses and 3.3–3.6 mmol/L in the mothers (Moniz et al., 1985).
2.3.4. Storage
The total body content of potassium is about 40–55 mmol/kg body weight (bw) (Rastegar, 1990;
Agarwal et al., 1994; Crook, 2012; Bailey et al., 2014), which corresponds to 3–4 moles (110–150 g)
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for a 70-kg adult. Similar potassium body contents (expressed per kg body weight) have been
reported in infants and children (Fomon et al., 1982; Butte et al., 2000).
Based on 462 US children (232 boys and 230 girls) aged 3–18 years, no differences in total body
potassium were observed for boys and girls between 12 and 30 kg of weight and 100 and 135 cm of
height (about 10 years of age) (Flynn et al., 1972). Above these values, girls had less potassium per
centimetre of height and per kilogram of weight than boys. In a sample of 116 US children (66 boys
and 50 girls, aged 5–17 years), males had larger skeletal muscle (SM) and total body potassium (TBK)
compared to females, while the SM:TBK ratio did not differ between both sexes (Wang et al., 2007).
SM:TBK was positively correlated with age, weight and height (r = 0.62, r = 0.63, r = 0.86,
respectively; all p < 0.001). The Panel notes that total body potassium accumulation during growth
appears to reﬂect patterns of skeletal muscle gain.
2.3.5. Losses
Body potassium content is regulated by the balance between dietary intake and renal excretion. In
addition to urinary excretion, small quantities of potassium are excreted in the faeces and through the
skin.
2.3.5.1. Urine
The kidney is the main route of potassium excretion. Studies in humans reported average urinary
excretion of potassium between 77% and 92% of total dietary intake (Mickelsen et al., 1977; Pietinen,
1982; Holbrook et al., 1984; Tasevska et al., 2006; Yoshida et al., 2012). Urinary excretion of
potassium varies with dietary intake. According to results published by the Intersalt Cooperative
Research Group in late 1980s (Intersalt Cooperative Research Group, 1988), a typical range observed
with a mixed Western diet was 46–77 mmol/day.
Potassium is freely ﬁltered by the glomerulus. In healthy adults, the rate of potassium ﬁltration by
the glomerular capillaries is 756 mmol/day, considering a glomerular ﬁltration rate of 180 L/day
multiplied by a plasma potassium concentration of 4.2 mmol/L (Guyton and Hall, 2006).
The renal tubules are capable of reabsorbing and secreting potassium in response to various stimuli
(Rodenburg et al., 2014). The human kidney efﬁciently excretes potassium in response to high dietary
intakes, but is less capable of sparing potassium when dietary intake is low (Kee et al., 2010).
The majority of ﬁltered potassium is reabsorbed in the proximal tubule and loop of Henle, so that
less than 10% of the ﬁltered load reaches the distal nephron. In the proximal tubule, potassium
absorption is primarily passive and proportional to sodium and water. Potassium reabsorption in the
thick ascending limb of Henle occurs through both transcellular and paracellular pathways. The
transcellular component is mediated by the Na+-K+-2Cl cotransporter located on the apical
membrane. Potassium secretion begins in the early distal convoluted tubule and progressively
increases along the distal nephron into the cortical collecting duct, where active reabsorption of
sodium is accompanied by excretion of potassium into the lumen (Palmer, 2014). Most urinary
potassium can be accounted for by electrogenic potassium secretion mediated by principal cells in the
initial collecting duct and the cortical collecting duct (Gumz et al., 2015). An electroneutral potassium
and chloride cotransport mechanism is also present on the apical surface of the distal nephron
epithelium. Potassium can be reabsorbed in the collecting duct, in situations of potassium depletion.
This process is mediated by upregulation of the apically located H+/K+-ATPase on alpha-intercalated
cells (Sansom and Welling, 2007; Palmer, 2014; Gumz et al., 2015).
The major factors regulating potassium excretion include dietary potassium, distal nephron ﬂow
rate and sodium delivery, mineralocorticoids (including aldosterone), and acid–base balance (Palmer,
2014; Gumz et al., 2015). Renal potassium excretion has also a circadian rhythm independent of food
intake (Gumz et al., 2015). The circadian rhythm, which originates from the brain, is transmitted to
circadian clocks in the tubule cells responsible for variations in potassium excretion. As a result,
potassium excretion is enhanced during the daylight phase and reduced during the night time phase
(Gumz et al., 2015).
During pregnancy, potassium excretion is held constant through adaptive mechanisms of renal
tubular potassium reabsorption, which adjust to the increased ﬁltered potassium load and the
increased retention of sodium mediated by aldosterone (Ehrlich and Lindheimer, 1972; Brown et al.,
1986; Cheung and Lafayette, 2013). Progesterone, through its antikaliuretic effect, has been proposed
to contribute to maintain potassium homeostasis in pregnant women (Lindheimer et al., 1987; Elabida
et al., 2011).
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2.3.5.2. Faeces
Potassium concentration in faeces is highly variable (ranging from 20 to 200 mmol/L). Distal ileum
and the colon can actively secrete potassium (Sorensen et al., 2010) (Section 2.3.1). Net absorption
only takes place when large gradients of concentration between the colon and the blood are present
(Devroede and Phillips, 1969).
Faecal potassium excretion is about 10–25 mmol/day, constituting 10–20% of total potassium
elimination from the body (Holbrook et al., 1984; Agarwal et al., 1994; Tasevska et al., 2006). Faecal
potassium excretion increases with ﬁbre intake (Cummings et al., 1976; Tasevska et al., 2006).
Potassium losses in faeces may considerably increase in pathological situations, especially in cases of
diarrhoea (Sandle and Hunter, 2010; West and von Saint Andre-von Arnim, 2014) or renal insufﬁciency
(Sandle et al., 1986).
In a study on four adult men in which dietary potassium intake was severely restricted (less than
39 mg (1 mmol)/day) for 2–7 days, faecal potassium loss decreased and was 2.5–7.6 mmol/day at the
end of the depletion period (Squires and Huth, 1959). This is presumed to represent obligatory
potassium losses related to digestive secretions (salivary, gastric, biliary and pancreatic), cell
desquamation, and mucus secretion (Agarwal et al., 1994; Sorensen et al., 2010).
2.3.5.3. Dermal losses
The concentration of potassium in the sweat is relatively low; typical values range from 3 to
7 mmol/L (Costill, 1977; Montain et al., 2007; Penney, 2008; Baker et al., 2009; Kilding et al., 2009;
Maughan et al., 2009). In various studies, the concentration of potassium in the sweat was not or only
minimally affected by physical exercise (Montain et al., 2007), heat stress (Malhotra et al., 1976) or
dietary sodium intake or ethnicity (Palacios et al., 2010), including conditions of dietary potassium
restriction (Malhotra et al., 1981; Costill et al., 1982). Sweat potassium concentration stays relatively
constant, regardless of sweat rate, level of acclimatisation or an individual’s sodium concentration in
the sweat (Weschler, 2008).
When sweat losses are several litres a day, as under heat or physical exercise stress conditions,
potassium sweat losses may be up to 10–25 mmol/day (Consolazio et al., 1963; Malhotra et al., 1976,
1981).
The Panel considers that potassium losses through the sweat at moderate physical activity
performed around thermoneutrality are likely to be in the range of 2–3.5 mmol/day, assuming a daily
sweat volume of around 0.5 L/day (Shirreffs and Maughan, 2005; Subudhi et al., 2005).
2.3.5.4. Breast milk
There is a decline in breast milk potassium concentration over the ﬁrst weeks of lactation, with a
high concentration in colostrum followed by a decrease (Atkinson et al., 1995). In longitudinal studies,
potassium concentration in breast milk, once mature, was nearly constant (Nagra, 1989; Allen et al.,
1991; Wack et al., 1997). Potassium concentration in breast milk shows diurnal variations, reciprocal to
sodium concentration (Keenan et al., 1982, 1983).
Atkinson et al. (1995) collected data on the potassium content in breast milk from nine studies
conducted in the USA, Canada and the UK. Mean potassium concentrations across studies were
between 682 and 725 mg/L (17.4 and 18.5 mmol/L) at day 3 (colostrum), 569 and 659 mg/L (14.5
and 16.8 mmol/L) at day 14 (transitional milk), 464 and 600 mg/L (11.9 and 15.3 mmol/L), 405 and
542 mg/L (10.3 and 13.9 mmol/L), and 366 and 495 mg/L (9.4 and 12.7 mmol/L) at day 30, 90 and
180 of lactation (mature milk), respectively.
Appendix A reports data on potassium concentration in breast milk from additional studies which
involved mothers of term infants in Western populations. Mean/median potassium concentrations are
between 461 and 594 mg/L (11.8 and 15.2 mmol/L) from six studies which analysed mature breast
milk (Keenan et al., 1982; Parr et al., 1991; Holt, 1993; Wack et al., 1997; Fly et al., 1998; Witczak
and Jarnuszewska, 2011) and 450 and 633 mg/L (11.5 and 16.2 mmol/L) in two studies which used
mixed samples (collected between 1 and 8 weeks post-partum) (Bauer and Gerss, 2011; Bjorklund
et al., 2012).
Based on available data, the Panel considers an approximate midpoint of potassium concentration
in mature breast milk of women from Western countries of 500 mg (12.8 mmol)/L. Based on a mean
milk transfer of 0.8 L/day (Butte et al., 2002; FAO/WHO/UNU, 2004; EFSA NDA Panel, 2009) during
the ﬁrst 6 months of lactation in exclusively breastfeeding women, the Panel estimates the maternal
loss of potassium through breast milk to be 400 mg (10.2 mmol)/day.
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2.3.6. Interaction with other nutrients
2.3.6.1. Sodium
The metabolism of potassium and sodium are strongly interrelated, principally due to the
Na+/K+-ATPase. Sodium/potassium interactions are important at the cellular level (Adrogue and
Madias, 2014). The renal regulation of sodium homeostasis is closely related to that of potassium
(Section 2.3.5.1). However, sodium intake does not inﬂuence potassium excretion except at high
sodium intakes (≥ 4,830 mg (210 mmol)/day) (Kirkendall et al., 1976; Luft et al., 1982). In the Dietary
Approaches to Stop Hypertension (DASH) study, at sodium intakes of 1,500 mg (65 mmol), 2,400 mg
(104 mmol) and 3,200 mg (140 mmol) per day for 4 weeks each, urinary potassium excretion did not
exceed intake (1,600  500 mg/day) and was similar at each sodium level (Sacks et al., 2001).
Salt sensitivity, deﬁned as either the reduction in blood pressure in response to a lower sodium
chloride intake or the rise in blood pressure in response to sodium loading (IOM, 2005), is a condition
frequently observed in African Americans and is also associated with genetic or physiological factors
(Weinberger, 1996; Strazzullo et al., 2000). Dietary potassium intake modulates the variation of blood
pressure levels due to salt sensitivity in normotensive (Luft et al., 1979; Morris et al., 1999; Wilson
et al., 1999), as well as in hypertensive individuals (Krishna et al., 1989; Coruzzi et al., 2001).
There is also evidence that the effect of potassium intake on blood pressure may be higher in
individuals with high sodium chloride intake compared to those with low sodium chloride intake and
that the sodium-to-potassium intake ratio may also inﬂuence this relationship (Section 5.6.1.1).
The Panel notes the interaction of potassium and sodium in relation to their metabolism and health
effects, particularly under conditions of sodium load or in salt-sensitive individuals.
2.3.6.2. Interactions with other minerals and vitamins
Calcium
Potassium depletion enhances urinary loss of calcium. In a study of six male and two female adults
who underwent 5 days of potassium deprivation, increases in both fasting and 24-h urinary calcium
excretion were observed; levels returned to normal within 5 days after termination of potassium
deprivation (Lemann et al., 1991).
In contrast, potassium supplementation may decrease urinary calcium excretion. Ten male and
female adults aged 21–41 years on a controlled diet containing on average 3,323  235 mg
(85  6 mmol) potassium/day, 866  36 mg (21.6  0.9 mmol) calcium/day and 3,795  322 mg
(165  14 mmol) sodium/day, were supplemented with 90 mmol/day of potassium bicarbonate or
potassium chloride (3,510 mg potassium) for 4 days. Potassium bicarbonate, but not potassium
chloride, reduced fasting and 24-h urinary calcium excretion (Lemann et al., 1991). In a meta-analysis,
Lambert et al. (2015) found that supplementation with alkaline potassium salts reduced calcium
excretion compared to a placebo (14 trials, potassium supplemental daily doses 1,170–7,020 mg
(30–180 mmol)). In studies which compared alkaline potassium salts with potassium chloride, a higher
effect of the alkaline salt on calcium excretion was observed. The Panel notes that most studies used
alkaline potassium salts and the independent effect of potassium as compared to alkali administration
on calcium excretion is unclear.
Phosphorus and vitamin D
Administration of potassium salts may alter renal tubular phosphate transport and renal synthesis of
1,25(OH)2-vitamin D and may increase serum phosphorus concentration (Lemann et al., 1991).
Sebastian et al. (1990) studied the effect of potassium supplementation (6,084 mg (156 mmol)/day as
potassium bicarbonate and potassium chloride for 8 days each) in six healthy males (25–40 years) on
a ﬁxed diet (3,220 mg (140 mmol) sodium, 2,024 mg (52 mmol) potassium, 361 mg (9 mmol)
calcium, 836 mg (27 mmol) phosphorus per 70-kg body weight). Both potassium forms caused an
increase in serum phosphorus and a decrease in 1,25(OH)2-vitamin D compared to a control period in
which no supplement was administrated.
The Panel considers that interactions between potassium and other minerals and vitamins, in the
context of a mixed European diet, are not relevant for setting dietary reference values (DRVs) for
potassium.
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2.4. Biomarkers
2.4.1. Biomarkers of intake
In healthy people, a large proportion (about 90%) of dietary potassium intake is absorbed
(Section 2.3.1). Urine is the major route of potassium excretion, while the remaining part is eliminated
in the faeces and, to a lesser extent, in sweat (Section 2.3.5). Recovery rates of dietary potassium in
the urine between 77% and 92% have been reported (Mickelsen et al., 1977; Pietinen, 1982; Holbrook
et al., 1984; Tasevska et al., 2006; Yoshida et al., 2012). In the study by Holbrook et al. (1984),
duplicate samples of meals and beverages and all urine from 12 men and 16 women were collected
daily for four 1-week periods and the potassium content was analysed to estimate the dietary intake
and urinary excretion of potassium. Mean ( SEM) urinary potassium excretion was 77  1.7% of
potassium intake. Tasevska et al. (2006) conducted a controlled feeding study in which seven men and
six women were hosted in a metabolic suite for 30 days. All urine and dietary duplicates were collected
for potassium analysis. On average ( SD), 77  6.7% of analysed potassium intake was excreted in
the urine. High correlations between 24-h urinary potassium excretion and potassium dietary intake
were found in both studies (r = 0.82 and 0.89, respectively). Some studies have indicated a lower
urinary excretion of potassium in black as compared to white individuals, although it is unclear
whether it reﬂects differences in potassium intakes or other factors (Voors et al., 1983; Barlow et al.,
1986; Langford et al., 1991; Wong et al., 2003; Aviv et al., 2004; Turban et al., 2013). Conversion
factors of 1.25 (Freedman et al., 2004, 2015) or 1.3 (Murakami et al., 2007; WHO, 2012b,d, Aburto
et al., 2013) have been proposed to estimate daily dietary potassium intake from 24-h urinary
potassium excretion. The Panel notes that the percentage of dietary intake recovered in the urine,
although quite consistent in different studies, shows a signiﬁcant interindividual variability, probably in
part due to inaccuracies in dietary assessment, errors in urine collections and/or other environmental
or genetic factors.
Several equations have been proposed to estimate 24-h urinary potassium excretion from a single
morning fasting urine sample (Kawasaki et al., 1993) or random spot urine sample (Tanaka et al.,
2002). Using data from 1,083 individuals (35–70 years) who provided both single fasting morning
and 24-h urinary samples, Mente et al. (2014) reported interclass correlation coefﬁcients between
formula-based and measured 24-h potassium excretion of 0.55 (95% CI = 0.31–0.69) for the Kawasaki
formula and 0.36 (95% CI = 0.07–0.60) for the Tanaka formula. Both methods were found to
underestimate actual potassium excretion. In contrast, in another validation study where 24-h and
random spot urine samples were collected from 147 women (19–26 years), Hooft van Huysduynen
et al. (2014) found that the Tanaka formula overestimated actual 24-h urinary potassium excretion. No
validation study used chemical analysis of dietary duplicates. The Panel notes that approaches based
on spot urine samples may be of some value in population studies but they require cautious
interpretation due to the risk of both over- or underestimation of potassium excretion. The Panel notes
that they provide imprecise estimates at individual level.
Measures of 24-h potassium excretion in urine have been used for validating dietary questionnaires.
Based on data from ﬁve validation studies, Freedman et al. (2015) reported average correlation
coefﬁcients of 0.37 with food frequency questionnaires (FFQs) and of 0.47 with a single 24-h recall.
A few studies have examined urinary potassium excretion in children and reported values between
1.3 and 1.8 mmol/kg bw per day (Knuiman et al., 1988; Zwiauer et al., 1991; Kristbjornsdottir et al.,
2012). However, in the absence of data for dietary potassium intakes (analysed or calculated) in these
studies, the reliability of urinary potassium excretion as a biomarker of dietary intake in children cannot
be assessed.
The Panel considers that urinary potassium excretion, based on 24-h collection, is a reliable
biomarker of dietary intake in adults on a population basis. However, the Panel notes that a single
24-h urinary collection can not accurately assess an individual’s usual intake. For converting 24-h
urinary potassium excretion values into potassium daily intakes (Section 5.6.1), the Panel selected a
factor of 1.30, based on the ratio of potassium dietary intake to urinary excretion reported in two
studies which used chemical analysis of the diet and 24-h urinary collection (Holbrook et al., 1984;
Tasevska et al., 2006). This factor has also been applied by other authors (Murakami et al., 2007;
WHO, 2012b,d, Aburto et al., 2013).
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2.4.2. Biomarkers of status
In healthy individuals, homeostatic mechanisms act to maintain blood potassium concentrations
within a narrow range (Section 2.3). Changes in extracellular potassium concentration as the result of
changes in external potassium equilibrium (i.e. balance between potassium intake and output) usually
occur slowly and are buffered by homeostatic changes in internal potassium equilibrium (i.e. shifts
between the extra- and intracellular ﬂuids) (Lorenz, 2012). As a result, plasma potassium
concentration is a late indicator of changes in potassium balance. In addition, low plasma potassium
concentrations can coexist with both normal and low total body potassium content (Section 2.2.2.1).
Thus, in most instances, serum potassium concentration does not accurately reﬂect total body
potassium content.
Whole body counting of 40K has been proposed for the determination of total body potassium
content (Tyson et al., 1970) and has been used for the assessment of body composition (Forbes,
1987; Dittmar and Reber, 2004; Murphy et al., 2014). This method permits a reliable estimate of total
body potassium (Forbes, 1987; Hansen and Allen, 1996). Like blood potassium concentration, total
body potassium content is only minimally affected by variations in dietary potassium intake. Total body
potassium depletion is usually caused by excessive potassium losses (through urine, diarrhoea or
vomiting) associated with certain health conditions or medicines (Section 2.2.2.1).
The Panel considers that there is no biomarker of potassium status which can be used for setting
DRVs for potassium in the general population.
2.5. Effects of genotypes
Genetic mechanisms may contribute to the blood pressure response to dietary potassium intake
(Section 5.6.1.1). In particular, different chromosome regions (Kelly et al., 2010) or genetic variants
(Zhao et al., 2010; He et al., 2011; Liu et al., 2013) were found to be associated with the individual
variability of the blood pressure response to oral potassium intake (‘potassium sensitivity’).
The Panel considers that, although genetic factors may affect the individual blood pressure
response to dietary potassium intake, no genotypes have yet been identiﬁed that would require
consideration with regard to the derivation of DRVs for potassium in the general population.
3. Dietary sources and intake data
3.1. Dietary sources
Potassium is present in all natural foods, in particular starchy roots or tubers, vegetables, fruits,
whole grains, dairy products and coffee. Substantial potassium losses may occur during food
processing. Drinking water and many food additives also contain potassium; however, it is unlikely that
they represent major sources.
Potassium as potassium-L-ascorbate, magnesium potassium citrate, potassium iodide, potassium
iodate, potassium bicarbonate, potassium carbonate, potassium chloride, potassium citrate, potassium
gluconate, potassium glycerophosphate, potassium lactate, potassium hydroxide, potassium salts of
orthophosphoric acid and potassium ﬂuoride may be added to both foods3 and food supplements,4
whereas potassium sulfate, potassium L-pidolate, potassium malate and potassium molybdate may only
be used in the manufacture of food supplements.4 The potassium content of infant and follow-on
formulae5 and processed cereal-based foods and baby foods for infants and young children6 is
regulated.
3 Regulation No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins and
minerals and of certain other substances to foods, OJ L 404, 30.12.2006, p. 26.
4 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the
Member States relating to food supplements, OJ L 183, 12.7.2002, p. 51.
5 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive
1999/21/EC, OJ L 401, 30.12.2006, p. 1.
6 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and
young children, OJ L 339, 6.12.2006, p. 16.
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3.2. Dietary intake
EFSA estimated dietary intakes of potassium from food consumption data available through the
EFSA Comprehensive Food Consumption Database (EFSA, 2011b), classiﬁed according to the food
classiﬁcation and description system FoodEx2 (EFSA, 2011a). Data from 13 dietary surveys in nine
countries of the European Union (EU) were used. The countries included were Finland, France,
Germany, Ireland, Italy, Latvia, the Netherlands, Sweden and the UK. The data covered all age groups
from infants to adults (Appendix B).
Nutrient composition data for potassium were derived from the EFSA Nutrient Composition
Database (Roe et al., 2013). Food composition information from Finland, France, Germany, Italy, the
Netherlands, Sweden and the UK were used to calculate potassium intakes in these countries,
assuming that the best intake estimate would be obtained when both the consumption data and the
composition data are from the same country. For nutrient intake estimates of Ireland and Latvia, food
composition data from the UK and Germany, respectively, were used, because no speciﬁc composition
data from these countries were available. The amount of borrowed potassium values (i.e. values taken
from other tables or databases) varied between 15% (Germany) and 84% (Sweden) in the seven
composition databases used; in all the countries except Germany, the percentage of borrowed values
was higher than 55% of the total. Estimates were based on the consumption of food, including salt
substitutes where available, but not dietary supplements.
Data on infants were available from Finland, Germany, the UK and Italy. The proportions of
breast-fed infants were 58% in the Finnish survey, 40% in the German survey, 44% in the Italian
survey and 21% in the UK survey. For the Italian and German surveys, breast milk intake estimates
were derived from the number of breastfeeding events recorded per day multiplied by standard
breast milk amounts consumed on an eating occasion at different ages. For the UK survey, the
amount of breast milk consumed was either directly quantiﬁed by the mother (expressed breast milk)
or extrapolated from the duration of each breastfeeding event. In the Finnish survey, information was
limited to whether infants were breastfed or not, and the contribution of breast milk to potassium
intakes could not be taken into consideration. The Panel notes the limitations in the methods used for
assessing breast milk consumption in infants and related uncertainties in the intake estimates for
infants (Appendices C and D).
Average potassium intakes across countries ranged between 821 and 1,535 mg/day (279–546 mg/MJ)
in infants (< 1 year, four surveys), between 1,516 and 2,005 mg/day (356–495 mg/MJ) in children
aged 1 to < 3 years (ﬁve surveys), between 1,668 and 2,750 mg/day (284–473 mg/MJ) in children aged
3 to < 10 years (seven surveys), between 2,093 and 3,712 mg/day (280–464 mg/MJ) in children aged
10 to < 18 years (seven surveys), and between 2,463 and 3,991 mg/day (338–497 mg/MJ) in adults
(≥ 18 years, eight surveys). Average daily intakes were in most cases slightly higher in males (Appendix C)
compared to females (Appendix D), mainly due to larger quantities of food consumed per day.
The main food groups contributing to potassium intakes were starchy roots or tubers and products
thereof, sugar plants, grains and grain-based products, milk and dairy products, and vegetables and
vegetable products (Appendices E and F). In the youngest population, food products for young
population (infants), and milk and dairy products (toddlers and other children) were the most
important contributors. In infants, in some surveys, the average contribution of food products for
young population represented more than 50% of the total intake of potassium. The impact of milk and
dairy products on the intake of potassium in this age class was also quite important, with average
contributions up to 22% of the total.
The EFSA intake estimates were compared with the published intake estimates from the same
national surveys and age ranges (Appendix G). The differences between the EFSA estimates and those
published were always below 10%, except for male adolescents in the German EsKiMo study where
the EFSA estimates were 12% higher than the published ones. Published data on potassium intake
were also available from the UK diet and nutrition survey of infants and young children (DNSIYC) 2011
survey but comparisons with the EFSA estimates were difﬁcult as they were reported by ethnic groups
and socioeconomic classes. Overall, the EFSA average estimates for infants (1,370–1,535 mg/day)
and toddlers (1,688–1,794 mg/day) were slightly higher than those reported in that survey
(1,024–1,161 mg/day for infants, 1,433–1,633 mg/day in toddlers). Several sources of uncertainties
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may contribute to the differences between the EFSA estimates and those published, including
inaccuracies in mapping food consumption data according to FoodEx2 classiﬁcation, analytical errors or
errors in estimating potassium, which may cause both too high and too low estimates of potassium
intake. As the intake calculations rely heavily on estimates of both food composition and food
consumption, it is not possible to conclude which of these intake estimates would be closer to the
actual potassium intake of the respective population groups.
4. Overview of dietary reference values and recommendations
4.1. Adults
The Nordic countries (Nordic Council of Ministers, 2004, 2014) based their recommendations on the
favourable effect of potassium on blood pressure (Intersalt Cooperative Research Group, 1988; Jula
et al., 1990; Appel et al., 1997; Geleijnse et al., 1997, 2003; Whelton et al., 1997; Sacks et al., 1998,
2001; Gu et al., 2001; Naismith and Braschi, 2003; Dickinson et al., 2006; van Bommel and Cleophas,
2012). The recommended intakes for potassium were set at 3,500 mg (90 mmol)/day for men and
3,100 mg (80 mmol)/day for women. It was noted that potassium intakes ‘somewhat over and above
these values might have further beneﬁcial effects’. A lower limit of 1,600 mg (40 mmol)/day was
proposed.
The WHO conducted a systematic review to explore the relationship between potassium and blood
pressure in adults (WHO, 2012b), which served as the basis for setting a strong recommendation7 for an
increase in potassium intake from food for reduction of blood pressure and risk of cardiovascular
disease, stroke, and coronary heart disease in adults, and for suggesting a conditional recommendation8
for an intake of 3,510 mg (90 mmol)/day for adults (WHO, 2012a).
The German-speaking countries (D-A-CH, 2015) considered that observed intakes of adults
between 2,000 and 3,000 mg (50–75 mmol)/day from common diets in Central Europe are sufﬁcient
under normal conditions. An amount of 2,000 mg (50 mmol)/day was designated an estimated value
for a minimal intake.
The US Institute of Medicine (IOM, 2005) set an adequate intake (AI) of 4,700 mg (120 mmol)/day
based on data on the amount of potassium found to eliminate severe salt sensitivity in African
American men (Morris et al., 1999) and considering the decreased risk of kidney stones observed in a
3-year intervention trial (Barcelo et al., 1993) and three epidemiological studies (Curhan et al., 1993,
1997; Hirvonen et al., 1999). Data from studies in non-hypertensive individuals were considered
supportive of this level of intake as a means to lower blood pressure. Epidemiological studies also
suggested that higher levels of potassium intake from foods were associated with decreased bone loss,
mainly when potassium is associated with bicarbonate precursors (New et al., 1997, 2000, 2004;
Tucker et al., 1999; Jones et al., 2001; Macdonald et al., 2004). For older adults, although less energy
is consumed, there is an increased risk of elevated blood pressure; therefore, the value was not
adjusted.
Afssa (2001) considered that the usual potassium intakes of 2,000–6,000 mg (50–150 mmol)/day
by the general population (Burgess et al., 1999) exceeds the estimated minimum requirement of
390–585 mg (10–15 mmol)/day. No DRV was derived.
The SCF (1993) suggested a lowest threshold intake of 1,600 mg (40 mmol)/day, to avoid low
plasma concentrations and loss of total body potassium (Sebastian et al., 1971). An average
requirement (AR) was not set. Using evidence from studies investigating the relationship between
potassium intake and blood pressure (Matlou et al., 1986; Rose, 1986; Intersalt Cooperative Research
Group, 1988; Krishna et al., 1989), the PRI was set at 3,100 mg (80 mmol)/day.
The UK DH (1991) estimated the requirements based on a factorial approach considering daily
potassium losses. The Reference Nutrient Intake (RNI) for adults was set at 3,500 mg (90 mmol)/day.
It set a Lower Reference Nutrient Intake (LRNI) of 2,000 mg (50 mmol)/day. No AR was derived.
An overview of DRVs for potassium for adults is given in Table 1.
7 A strong recommendation is one for which the guideline development group is conﬁdent that the desirable effects outweigh
the undesirable effects.
8 A conditional recommendation is one for which the guideline development group concludes that the desirable effects of
adherence probably outweigh the undesirable effects, but the group is not conﬁdent about the trade-off.
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4.2. Infants and children
For children and adolescents, the Nordic countries (Nordic Council of Ministers, 2014) extrapolated
recommendations from adult values based on differences in body weight and needs for growth. PRIs
of 1,800 mg (46 mmol)/day and 2,000 mg (51 mmol)/day were set for children aged 2–5 and
6–9 years, respectively. For boys and girls aged 10–13 years, the PRI are 3,300 mg (84 mmol)/day
and 2,900 mg (74 mmol)/day, respectively.
The WHO (2012a) suggested an increase in potassium intake from food to control9 blood pressure
in children based on an observational study (Geleijnse et al., 1990) and a systematic review in adults
(WHO, 2012b). Based on the energy requirements of children relative to those of adults, a conditional
recommendation for potassium intake of at least 3,510 mg (90 mmol/day) was set.
The German-speaking countries (D-A-CH, 2015) estimated potassium needs to maintain electrolyte
homeostasis and for growth of cellular mass. It was considered that infants during the ﬁrst 4 months
of life, because of their rapid growth, need 35 mg (0.9 mmol)/day for the development of cellular
mass. Boys and girls up to 12 years need 16–20 mg (0.4–0.5 mmol)/day. For the period of accelerated
growth in puberty, 35 mg (0.9 mmol)/day is required (Fomon, 1993). The requirement for the
maintenance of homeostasis was estimated on the basis of total energy intake which, in turn, should
be proportional to cell mass and, thus, the body’s total potassium content.
For infants, the IOM (2005) proposed an AI that reﬂects the calculated mean potassium intake of
infants principally fed breast milk, or a combination of breast milk and complementary foods. For age
0–6 months, a mean potassium intake of 390 mg (10 mmol)/day was estimated based on an average
breast milk intake of 0.78 L/day (Keenan et al., 1982; Butte et al., 1984; Chandra, 1984; Neville et al.,
1988) and an average breast milk potassium concentration of 500 mg/L (Gross et al., 1980; Picciano
et al., 1981; Keenan et al., 1982; Lemons et al., 1982; Dewey and L€onnerdal, 1983). For age
6–12 months, the average potassium intakes were estimated at 300 mg (8 mmol)/day from
breast milk considering an average intake of milk of 0.6 L/day (Heinig et al., 1993) and 440 mg
(11 mmol)/day from complementary foods. After rounding, the AI was set at 700 mg (18 mmol)/day
for this age group. Due to a lack of evidence in children, the AI for age 1–18 years was extrapolated
from the AI for adults based on energy intake (IOM, 2000). This was a conservative choice because of
concern that adjustment based on weight might lead to a relatively low and potentially inadequate
value; it was considered that greater intake of potassium could also mitigate the effects of high
sodium intake associated to the high energy intake relative to weight observed in children.
As for adults, Afssa (2001) considered that the usual potassium intakes of children cover the
minimum requirement and did not set a DRV.
The SCF (1993) and the UK DH (1991) concluded that there is a lack of evidence on basal
potassium losses in children. The two committees considered urinary excretion of 27–90 mg/kg bw per
day (0.7–2.3 mmol/kg bw per day) and an amount needed for growth and lean tissue synthesis of
2,000 mg/kg bw. With these and other factors to allow for faecal losses and for integumental losses,
PRIs for children were estimated factorially.
An overview of DRVs for potassium for infants and children is given in Table 2.
Table 1: Overview of dietary reference values for potassium for adults
D-A-CH
(2015)(b)
NCM
(2014)(a)
WHO
(2012a)(c)
IOM
(2005)(d)
Afssa
(2001)(d)
SCF
(1993)(a)
DH
(1991)(a)
Age (years) ≥ 19 ≥ 18 ≥ 16 ≥ 19 ≥ 20 ≥ 18 ≥ 19
DRV men (mg/day) 2,000 3,500 ≥ 3,510 4,700 – 3,100 3,500
DRV women (mg/day) 2,000 3,100 ≥ 3,510 4,700 – 3,100 3,500
Afssa: Agence francaise de securite sanitaire des aliments; D-A-CH: Deutschland-Austria-Confoederatio Helvetica; DH: Department
of Health; DRV: dietary reference value; IOM: US Institute of Medicine of the National Academy of Sciences; NCM: Nordic Council
of Ministers; SCF: Scientiﬁc Committee for Food; WHO: World Health Organization.
(a): Population reference intake.
(b): Adequate minimal intake.
(c): Suggested intake.
(d): Adequate intake.
9 ‘Control’ for this recommendation refers to the prevention of a deleterious rise in blood pressure with age.
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4.3. Pregnancy and lactation
The Nordic and the German-speaking countries as well as the SCF considered that pregnancy and
lactation do not impose an additional potassium requirement (SCF, 1993; Nordic Council of Ministers,
2014; D-A-CH, 2015).
The IOM (2005) concluded that potassium accretion during pregnancy is very small and that data are
not sufﬁcient to suggest a different requirement for potassium during pregnancy. Therefore, the AI was
the same as for non-pregnant women. An AI of 5,100 mg (130 mmol)/day was set for lactation,
considering an additional need of around 400 mg (10 mmol)/day of potassium. This was based on an
average potassium concentration of breast milk of 500 mg/L (Gross et al., 1980; Picciano et al., 1981;
Keenan et al., 1982; Lemons et al., 1982; Dewey and L€onnerdal, 1983) and an average milk production
of approximately 0.78 L/day (Keenan et al., 1982; Butte et al., 1984; Chandra, 1984; Neville et al.,
1988), during the ﬁrst 6 months of lactation. In the absence of information to the contrary, it was
assumed that the efﬁciency of conversion of dietary potassium to milk produced is 100%.
The UK DH (1991) assumed that the RNI value would apply for all women in their reproductive years.
Afssa (2001) and WHO (2012a) gave no speciﬁc recommendations for pregnant and lactating women.
An overview of DRVs for potassium for pregnant and lactating women is given in Table 3.
Table 2: Overview of dietary reference values for potassium for infants and children
D-A-CH
(2015)(a)
Nordic Council of
Ministers (2014)(b)
IOM
(2005)(c)
SCF
(1993)(b)
DH
(1991)(b)
Age (months) 4–< 12 6–11 7–12 6–11 4–6
DRV (mg/day) 650 1,100 700 800 850
Age (months) – 12–23 – – 7–12
DRV (mg/day) – 1,400 – – 700
Age (years) 1–< 4 2–5 1–3 1–3 1–3
DRV (mg/day) 1,000 1,800 3,000 800 800
Age (years) 4–< 7 6–9 4–8 4–6 4–6
DRV (mg/day) 1,400 2,000 3,800 1,100 1,100
Age (years) 7–< 10 10–13 9–13 7–10 7–10
DRV boys (mg/day) 1,600 3,300 4,500 2,000 2,000
DRV girls (mg/day) 1,600 2,900 4,500 2,000 2,000
Age (years) 10–< 13 14–17 14–18 11–14 15–18
DRV boys (mg/day) 1,700 3,500 4,700 3,100 3,500
DRV girls (mg/day) 1,700 3,100 4,700 3,100 3,500
Age (years) 13–< 15 – – 15–17 –
DRV (mg/day) 1,900 – – 3,100 –
Age (years) 15–< 19 – – – –
DRV (mg/day) 2,000 – – – –
D-A-CH: Deutschland-Austria-Confoederatio Helvetica; DH: Department of Health; DRV: dietary reference value; IOM: US
Institute of Medicine of the National Academy of Sciences; NCM: Nordic Council of Ministers; SCF: Scientiﬁc Committee for Food.
(a): Adequate minimum intake.
(b): Population reference intake.
(c): Adequate intake.
Table 3: Overview of dietary reference values for potassium for pregnant and lactating women
IOM (2005)
Age (years) 14–50
AI pregnancy (mg/day) 4,700
AI lactation (mg/day) 5,100
AI, Adequate intake; IOM, US Institute of Medicine of the National Academy of Sciences.
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5. Criteria (endpoints) on which to base dietary reference values
5.1. Biomarkers as indicators of potassium requirement
Plasma potassium concentration and measures of total body potassium cannot be used for setting
DRVs for potassium (Section 2.4.2).
The Panel considers that there are no biomarkers of potassium status that can be used for deriving
DRVs for potassium in the general population.
5.2. Balance studies
Balance studies are based on the assumption that a healthy subject on an adequate diet maintains
an equilibrium or a null balance between nutrient intakes and nutrient losses; at this null balance, the
intake matches the requirement determined by the given physiological state of the individual. When
intakes exceed losses (positive balance), there is nutrient accretion that may be attributable to growth
or to weight gain, anabolism or repletion of stores; when losses exceed intakes (negative balance),
nutrient stores are progressively depleted resulting, in the long term, in clinical symptoms of
deﬁciency. In addition to numerous methodological concerns about accuracy and precision in the
determination of intakes and losses (Baer et al., 1999), the validity of balance studies for addressing
requirements has been questioned: they might possibly reﬂect only adaptive changes before a new
steady state is reached (Young, 1986), or they might reﬂect only the conditions for maintenance of
nutrient stores and exchangeable body pools in the context of a given diet, and the relevance for
health of the size of the pools still needs to be established for each nutrient (Mertz, 1987).
In the study by Holbrook et al. (1984) in the USA, 28 free-living adults, 12 men and 16 women
(20–53 years), consumed self-selected diets and maintained a daily dietary record for 1 year. During
four 7-day periods, one in each season of the year, duplicate samples of meals and beverages and all
urine and faeces for the same period were collected and analysed for potassium content by atomic
absorption spectrometry (AAS). Mean ( SEM) analysed intake of potassium was 3,300  100 mg
(84  2 mmol)/day for men and 2,400  600 mg (61  15 mmol)/day for women (mean analysed
intakes for the study group ranged from 2,600 to 2,900 mg (66–74 mmol)/day among the four
balance periods). Mean ( SEM) intake calculated from the dietary records was 2,900  100 mg
(74  2 mmol)/day for men and 2,100  100 mg (54  2 mmol)/day for women. The correlation
between urinary excretion and dietary intake of potassium was signiﬁcant (r = 0.92). Mean ( SEM)
apparent absorption of potassium was 84.5  0.6% and did not change signiﬁcantly over the range of
intakes. Mean ( SEM) balance calculated from the analysed potassium intake was positive,
+ 280  50 mg/day. For the four study periods, mean balances were + 250 mg/day in spring,
+ 400 mg/day in summer, + 210 mg/day in autumn and + 280 mg/day in winter, respectively
(signiﬁcant difference between summer and autumn). The Panel notes that other losses of potassium,
including dermal losses (skin and sweat), were not measured, and these might explain the more
positive balance observed in the summer compared with the autumn.
Sriboonlue et al. (1999) undertook a 10-day balance study in 15 Thai men aged 25–50 years
(mean ( SD) body weight 63  9 kg) in two areas (no adaptation period). Subjects were given a
ﬁxed diet. Foods were weighed both before and after meals for each subject. Aliquots of foods
consumed were taken for potassium analysis. Potassium in urine and faeces were measured daily in all
subjects, however, potassium lost in the sweat was analysed only in one subject. The rural group
(n = 10) had a mean ( SD) potassium intake of 1,731  138 mg (44  4 mmol)/day and the urban
group (n = 5) had a mean intake of 1,839  145 mg (47  4 mmol)/day (not signiﬁcantly different).
Urinary and faecal excretions of potassium were 721  129 and 148  25 mg/day in the rural group
and 919  186 and 164  21 mg/day in the urban group, resulting in potassium balances of
+ 860  140 in the rural group and + 756  222 mg/day in the urban group, respectively. Regression
of potassium balance vs intake indicated that rural and urban subjects needed potassium intakes
of 832 and 884 mg (21 and 23 mmol)/day to stay in balance. For the one participant in whom
sweat potassium was measured, mean balance over the 10 days was + 847  373 mg/day and
+ 396  344 mg/day without and with subtraction of sweat potassium excretion. The authors reported
high ambient temperatures during the study period (mean ( SD): 30.9  1.7°C at 12.00 a.m. and
35.2  2.0°C at 3.00 p.m.) and substantial sweat losses (mean ( SD): 1,927  420 mL/day for
the rural subjects and 1,759  408 mL/day for the urban subjects, roughly estimated by subtracting
the 24-h urine volume from the daily water intake). The Panel notes the lack of an adaptation period,
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the small number of subjects, the fact that the study was conducted in a Thai population, under
particular environmental conditions, and the largely positive balance estimates. These may partly be
explained by the lack of consideration of potentially substantial potassium losses in the sweat
(Section 2.3.5.3). Consequently, the Panel considers that these data cannot be used to estimate the
potassium requirement of European people.
Eleven potassium balance studies were conducted in Japan between 1984 and 2000, which
involved 109 volunteers (23 males, 86 females; 18–28 years) (Kodama et al., 2005). The duration of
the study periods ranged from 5 to 12 days, with 2–4 days adaptation period. The diet of subjects was
controlled and duplicate diet samples were taken. Faeces and urine were collected throughout the
experiment. In six studies (n = 49), the arm sweat was collected during exercise on a bicycle
ergometer. Total sweat loss of potassium during exercise throughout the balance period was divided by
days of the balance period and expressed as sweat loss in mg/kg bw per day. The potassium content
of the diet, faeces, urine and sweat were measured by AAS. The mean dietary intakes of potassium
ranged between 1,830 and 3,610 mg (47 and 92 mmol)/day across studies. From the regression
equation describing the relationship between potassium intake and balance of all individuals, the mean
(95% CI) intake of potassium when potassium balance was null was 39 (37–42) mg/kg bw per day.
The Panel notes the short adaptation periods of the studies and the fact that they were conducted in
Japanese populations, and hence considers that this result cannot be used to estimate the potassium
requirement of European people.
Nishimuta et al. (2012) applied a similar approach to data from 13 balance studies conducted on
young Japanese women (n = 131, 18–26 years). As the median of the potassium balance distribution
was found to be positive, the authors adjusted the individual data to set the median value to zero,
under the assumption that the positive balance was due to the fact that some pathways of potassium
losses had not been assessed, as regulatory mechanisms would successfully maintain the balance at
zero. The Panel notes that this adjustment hampers the interpretation of this study.
Potassium balance studies have been found to underestimate potassium losses as compared with
repeated assays of body potassium content by the 40K counting method (Isaksson and Sjogren, 1963;
Forbes et al., 1981; Forbes, 1983). Several sources of error in the estimation of potassium balances
were proposed, including skin losses, other routes for losses (e.g. shaving, nail clipping), systematic
errors (systematic overestimation of intake and underestimation of output),and lack of appropriate
adaptation time.
The Panel notes that the relatively few available potassium balance studies are heterogeneous with
regard to the populations examined, the presence and duration of equilibration periods and the duration
of balance periods. The Panel notes the many limitations of these studies and considers that the data
derived from the available balance studies cannot be used for setting DRVs for potassium for adults.
5.3. Indicators of requirement in children
No balance studies on potassium on children have been identiﬁed.
During growth, total body potassium accumulation appears to reﬂect patterns of skeletal muscle
gain (Section 2.3.4). Butte et al. (2000) reported mean ( SD) total potassium body content of
6.0  0.9 g and 21.5  2.7 g in girls and of 6.4  0.7 g and 22.9  2.1 g in boys, at age 6 months
and 2 years, respectively (n = 76 children, mainly Caucasian). This corresponds to an increase in
potassium body content of about 16 g over 18 months. Based on a sample of 292 Caucasian children
aged 5–18 years, Ellis et al. (2000) found mean total body potassium content from 36.9  4.8 g to
100.0  41.8 g in girls aged 5–7 years and 17–19 years, respectively. In boys, the mean content was
41.9  6.4 g and 152.4  20.7 g at age 5–7 years and 17–19 years, respectively. This represents a
total accretion of potassium of 64 g in girls and 111 g in boys over a period of 12 years. From these
data, the net daily accretion of potassium in new tissues is estimated to range between ca. 10 and
50 mg/day depending on children’s age and sex. The Panel notes that net daily accretion of potassium
in new tissues only partly reﬂects children’s potassium requirement.
The Panel considers that there are no data relating to potassium requirement which can be used
for deriving DRVs for potassium for children.
5.4. Indicators of potassium requirement in pregnancy
Plasma potassium concentration has been observed to decrease during pregnancy by 0.2–0.4 mmol/L
(Brown et al., 1986; Lindheimer et al., 1987). Despite increased ﬁltered potassium load in the kidney
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and mineralocorticoid activity, healthy pregnant women do not typically develop hypokalaemia. Renal
reabsorption of potassium accompanies the physiological changes which occur during pregnancy and
urinary potassium excretion is held constant (Section 2.3.5.1).
Several studies have measured total body potassium in pregnant women using whole body counting.
From a cohort of 40 women in the UK followed as of 12–22 weeks of pregnancy, Godfrey and Wadsworth
(1970) estimated an accumulation of 307 mmol (12 g) potassium during pregnancy after correcting for
possible analytical underestimation due to the changes in mass and body shape. In a longitudinal study of
22 pregnant Swedish women, total body potassium content was of 2,397  327 mmol (93.5  12.7 g),
2,224  298 mmol (86.7  11.6 g), 2,290  330 mmol (89.3  13.0 g) and 2,507  307 mmol
(97.8  12.0 g) before pregnancy and at 16–18, 30 and 36 weeks of pregnancy, respectively (Forsum
et al., 1988). A total accretion of 283 mmol (around 11 g) potassium between weeks 16–18 and week 36
can be estimated from this study. In 34 US women with a normal body mass index (BMI), Butte et al.
(2003) reported total body potassium of 2,610  328 mmol (101.8  12.8 g), 2,543  343 mmol
(99.2  13.4 g), 2,602  338 mmol (101.5  13.2 g) and 2,777  382 mmol (108.3  14.9 g) before
pregnancy and at 9, 22 and 36 weeks of gestation, respectively. This would represent a total potassium
accretion of 234 mmol (around 9 g) potassium between week 9 and week 36 of pregnancy. Both studies
indicate that most potassium accretion occurs during the last trimester of pregnancy. During this period, a
daily accretion in the order of 3 mmol (120 mg) potassium can be estimated from these data.
A total content of potassium in mature fetuses and full-term neonates between about 100 mmol
(4 g) (Ellis et al., 1993) and 150 mmol (6 g) has been reported (Widdowson and Spray, 1951;
Widdowson, 1980). Ziegler et al. (1976) and Widdowson (1980) estimated potassium accretion in the
fetus based on data from chemical analyses of human fetuses (n = 22 and 38, respectively) and daily
increments of weight gain. Daily potassium accretion rate was found to increase progressively over the
course of pregnancy. Ziegler et al. (1976) found accretion rates from 0.5 mmol/day at 24–25 weeks to
1.5 mmol/day at 36–37 weeks. Widdowson (1980) reported values from 0.1 mmol/day at weeks
12–16 to 1.4 mmol/day at weeks 36–40 of pregnancy. Placental potassium content around 240 mmol/kg
dry weight has been reported (Challier et al., 1988). Considering a mean placenta dry weight of 92 g at
term (Hohler et al., 1972), this would correspond to a net transfer of potassium to placental tissues of
22 mmol (858 mg) over the whole pregnancy.
The Panel considers that the requirement for the daily accretion rate of potassium in fetal and
maternal tissues can be met by the adaptive changes which maintain potassium homeostasis during
pregnancy.
5.5. Indicators of potassium requirement in lactation
Data on body potassium content changes during lactation are very limited. In a sample of 40
lactating and 36 non-lactating women in the USA, signiﬁcantly greater losses in total body potassium
content, measured by whole body counting, were found in lactating women than non-lactating women
between 0.5 and 3 months post-partum (Butte and Hopkinson, 1998). The Panel notes that this
indicates that total body potassium content decreases in lactating women; however, no quantitative data
on the extent of potassium body losses in lactating vs non-lactating women are available from the paper.
Based on available data, the Panel estimates a loss of potassium of 400 mg (10 mmol)/day through
breast milk during lactation (Section 2.3.5.4).
5.6. Potassium intake and health consequences
The level of potassium intake has been reported to be associated with several health outcomes.
Most studies focused on its relation with cardiovascular endpoints and, in particular, blood pressure
and stroke. Several other outcomes, such as bone health and kidney stones and metabolic disease,
have also been investigated.
5.6.1. Cardiovascular disease-related outcomes
A large number of observational and intervention studies have addressed the relationship between
the dietary intake of potassium and risk of cardiovascular disease in adults, focusing on blood pressure
and hypertension, as well as the risk of stroke, ischaemic heart disease and arrhythmia. This section
summarises evidence mainly from meta-analyses of randomised controlled trials (RCTs) and
prospective observational studies on the relationship between potassium intake and cardiovascular
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disease-related outcomes, particularly blood pressure, stroke and coronary heart disease. Where
studies measured 24-h urinary potassium excretion as a marker of potassium intake, the Panel applied
a factor of 1.3 to estimate the corresponding daily potassium intake (Section 2.4.1).
5.6.1.1. Blood pressure
There is a direct relationship between blood pressure and risk of cardiovascular disease in the
general population. The Panel notes that blood pressure is a continuum and studies conducted in
people classiﬁed as hypertensive may inform the relationship between potassium intake and blood
pressure in the general population. The Panel also notes that raised blood pressure affects a large
proportion of the adult European population. According to WHO estimates, prevalence of raised blood
pressure (deﬁned as systolic and/or diastolic blood pressure equal to or above 140/90 mmHg) in
adults aged ≥ 25 years is 44.5% in males and 37.1% in females in the European region (WHO, 2010).
The Panel examined the data relating potassium intake to blood pressure when expressed as a
continuous variable from intervention studies conducted in normotensive and/or hypertensive people.
The Panel also reviewed the evidence, from observational studies, for an association between
potassium intake and the risk of developing hypertension. The Panel notes that different criteria may
have been used for deﬁning ‘hypertension’ across studies; the Panel uses the term as deﬁned by the
authors when describing the individual studies.
Data in adults
a) Evidence from randomised controlled trials
Several meta-analyses of RCTs have been conducted on the effect of potassium intake on blood
pressure. These include a Cochrane review (Dickinson et al., 2006), a meta-analysis commissioned by
the WHO (Aburto et al., 2013) as a basis for its guideline on potassium intake (WHO, 2012a), an
update of the latter by the Food Standards Australia New Zealand (FSANZ, 2014), and a more recent
meta-analysis by Binia et al. (2015). These meta-analyses differ with respect to their inclusion criteria.
The review by Dickinson et al. (2006) was limited to RCTs carried out in hypertensive subjects, with at
least 8 weeks of potassium intervention and with no other intervention than manipulation of the
potassium intake. Aburto et al. (2013), FSANZ (2014) and Binia et al. (2015) included RCTs in both
normotensive and hypertensive subjects, with a minimum period of potassium intervention of 4 weeks,
and which reported 24-h urinary potassium at the end of the intervention as a marker of potassium
intake. Aburto et al. (2013) and FSANZ (2014) included studies in hypertensive subjects with or
without blood pressure-lowering medication, while Binia et al. (2015) restricted the included studies to
those performed on hypertensive subjects without medication. For the three latter meta-analyses,
studies manipulating other dietary factors in addition to potassium intake (such as changes in sodium
intake) were eligible.
In the meta-analysis by Dickinson et al. (2006) in hypertensive subjects, ﬁve RCTs (n = 425) met the
inclusion criteria. Four studies used potassium supplements (between 1,872 mg (48 mmol) and
4,680 mg (120 mmol) per day; background intake levels were not reported), while in one study
participants were advised to increase their dietary intake of potassium (> 100 mmol/day). Potassium
supplementation compared to control resulted in an overall reduction in systolic blood pressure (SBP)
of 11.2 mmHg (95% CI = 25.2–2.7; I2 = 98%) and in diastolic blood pressure (DBP) of 5.0 mmHg
(95% CI = 12.5–2.4; I2 = 99%). Sensitivity analysis restricted to the two high quality trials found
overall reductions in SBP of 7.1 mmHg (95% CI = 19.9–5.7; I2 = 87%) and in DBP of 5.5 mmHg
(95% CI= 14.5–3.5; I2 = 87%). The Panel notes that all studies included involved hypertensive
subjects without blood pressure-lowering treatment. Despite the high heterogeneity, the Panel notes
that the point estimates obtained in both the overall analysis and with the high-quality studies suggest a
blood pressure-lowering effect of potassium supplementation. The Panel also notes that no additional
studies which meet the inclusion criteria of this meta-analysis have been published to date.
The meta-analysis by Aburto et al. (2013) included 21 RCTs (n = 1,892), of which 16 studies were
conducted in treated and untreated hypertensive subjects, three studies in normotensive subjects and
two studies in mixed populations. In the overall analysis, increased potassium intake, through
supplementation or dietary advice, reduced SBP by 3.49 mmHg (95% CI = 5.15 to 1.82; I2 = 65%)
and DBP by 1.96 mmHg (95% CI = 3.06 to 0.86; I2 = 55%) compared with the controls. When
restricting the assessment to the three studies in normotensive adults, no effect of potassium
supplementation on blood pressure was found. When only the studies in treated and untreated
hypertensive subjects were considered, an increased potassium intake reduced SBP (5.32 mmHg;
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95% CI = 7.20 to 3.43; I2 = 21%)) and DBP (3.10 mmHg; 95% CI = 4.53 to 1.66; I2 = 24%)).
Effects of potassium intake on blood pressure levels were also found in subgroup analyses according
to the use of blood pressure-lowering treatment (hypertensive subjects without treatment: SBP
change: 3.63 mmHg; 95% CI = 5.69 to 1.57; I2 = 72%; and DBP change: 1.37 mmHg;
95% CI = 2.50 to 0.23; I2 = 51%); pharmacologically-treated hypertensive subjects: SBP change:
5.85 mmHg; 95% CI = 10.61 to 1.08; I2 = 34%) and DBP change: 3.80 mmHg; 95%
CI = 8.25–0.66; I2 = 66%)).
Aburto et al. (2013) conducted subgroup analyses where studies were classiﬁed according to the
‘achieved’ potassium intake in the intervention groups (estimated by multiplying urinary potassium
following potassium supplementation by a factor of 1.30), the duration of the intervention, or the
population average sodium intake at baseline.
The ‘achieved’ potassium intake in the intervention group was below 3,500 mg (90 mmol)/day in
two studies, between 3,500 and 4,700 mg (90 and 120 mmol)/day in ﬁve studies, between 4,700 and
6,000 mg (120 and 155 mmol)/day in 11 studies, and ≥ 6,000 mg (155 mmol)/day in four studies.
The largest reduction in SBP and DBP was found in the subgroup characterised by an ‘achieved’
potassium intake of 3,500–4,700 mg (90–120 mmol)/day. The SBP and DBP changes were
7.16 mmHg (95% CI = 12.41 to 1.91; I2 = 71%) and 4.01 mmHg (95% CI = 8.44–0.42;
I2 = 75%), respectively. A reduction in blood pressure was already apparent in the subgroup of studies
with a potassium intake below 3,500 mg (90 mmol)/day. The Panel notes that all studies were
included in this subgroup analysis (i.e. studies in normotensive, hypertensive and mixed populations).
No separate subgroup analyses were carried out which included only studies in normotensive or
hypertensive people.
No effect of duration of intervention (< 2 months, 2–4 months and > 4 months) was found.
A larger blood pressure-lowering effect of potassium was observed in the subgroup of studies with
the highest baseline sodium intakes (> 4 g/day) compared to the subgroups of studies with lower
sodium intakes (< 2 g/day and 2–4 g/day).
The FSANZ (2014) revised the meta-analysis of Aburto et al. (2013) and included one newly
published study (Matthesen et al., 2012). The latter had found no effect of supplementation with
3,900 mg (100 mmol) potassium/day for 28 days on either 24-h ambulatory blood pressure or central
blood pressure in 21 Danish normotensive subjects, whose background potassium intake was around
3,800 mg (99 mmol)/day based on urinary potassium excretion. The revision and the update had a
limited impact on the overall effect estimates and the FSANZ concluded that the results of the analysis
from Aburto et al. (2013) remained valid.
The meta-analysis by Binia et al. (2015) included 14 RCTs. Most of the studies had a potassium
intervention of 2,340–2,535 mg/day (60–65 mmol/day), three had a potassium intervention of
1,560 mg/day (40 mmol/day) or less and one study had a potassium intervention of at least 4,680 mg
(120 mmol/day). The 24-h urinary potassium excretion increased to between 55 mmol (2,145 mg) and
200 mmol (7,800 mg) in the intervention groups. Results of overall analysis yielded an effect of
potassium intervention on SBP of 4.7 mmHg (95% CI = 7.0 to 2.4; I2 = 79%) and on DBP of
3.5 mmHg (95% CI = 5.7–1.3; I2 = 93%). When limiting the analysis to untreated hypertensive
subjects (10 trials), larger reductions in SBP and DBP were observed. Total daily urinary potassium
excretion between 2,300 and 3,900 mg (60 and 100 mmol)/day, corresponding to potassium intakes
from 2,900 to 4,900 mg (75–125 mmol), was associated with the highest blood pressure reduction; no
dose–response effect was identiﬁed. The Panel notes that subgroup analyses according to
normotensive vs hypertensive status were not carried out. The Panel notes that results from two of
the trials (Chalmers et al. (1986) and He et al. (2010)) were partially considered in the analysis and
that two eligible trials (Grobbee et al., 1987; Matthesen et al., 2012) were not included.
One additional RCT has become available since these meta-analyses were published. This involved
37 untreated (pre)hypertensive men and women (baseline SBP: 130–159 mmHg) given a potassium
supplement of 2,800 mg/day together with a controlled background diet (sodium: 2,400 mg/day;
potassium: 2,300 mg/day) for 4 weeks (Gijsbers et al., 2015). 24-h ambulatory blood pressure was
reduced in the intervention group compared to the control group (mean difference SBP 3.9 mmHg
(95% CI = 6.9 to 0.9); DBP 1.6 mmHg (95% CI = 3.2 to 0.1)). Ofﬁce SBP (3.0 mmHg,
95% CI = 6.7–0.6) but not DBP (0.3 mmHg, 95% CI = 2.1–1.6) was reduced in the intervention
group compared with the controls.
The Panel considers that there is evidence from RCTs for a beneﬁcial effect of potassium intake on
blood pressure in subjects classiﬁed as hypertensive (with or without medication), but not in subjects
classiﬁed as normotensive. The Panel further notes that in the analysis from Aburto et al. (2013),
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which combined studies in hypertensive and normotensive subjects, the largest reduction in SBP and
DBP was found in the subgroup characterised by an ‘achieved’ potassium intake of 3,500–4,700 mg
(90–120 mmol)/day, compared with lower and higher amounts.
b) Evidence from observational cohort studies
Two longitudinal observational studies assessed the association between urinary potassium
excretion and incidence of hypertension.
A study conducted in Taiwan included 1,520 middle-aged and older subjects who were free from
hypertension at baseline (Chien et al., 2008). Participants were asked to collect their overnight urine
and sleep time was recorded in order to estimate 24-h urinary excretion of potassium. Incident
hypertension cases were diagnosed according to ofﬁce blood pressure measurements and medication
history. During a median of 7.93 years of follow-up (interquartile range (IQR) 4.07–9.04 years), 669
cases of incident hypertension were documented. No association was found between potassium
excretion and risk of hypertension in a multivariate model. The Panel, however, notes the
methodological limitation of using an overnight urine collection to estimate daily potassium excretion.
Risk of hypertension was studied in 5,511 normotensive subjects of Caucasian origin from the
Netherlands, aged 28–75 years (Kieneker et al., 2014). This population was part of the Prevention of
Renal and Vascular End-Stage Disease (PREVEND) study, which recruited a cohort of 8,592 individuals
in 1997–1998, oversampling subjects with albuminuria (Kieneker et al., 2016). Potassium excretion was
measured in two 24-h urine specimens at baseline (1997–1998) and midway during follow-up
(2001–2003). Baseline median potassium excretion was 70 mmol/24 h (IQR 57–85 mmol/24 h), which
corresponds to a dietary potassium intake of approximately 3,500 mg (91 mmol)/day. The
within-subject correlations for potassium excretion between the paired 24-h urine collections at the
ﬁrst and second examinations were r = 0.59 (p < 0.0001; n = 5,489) and r = 0.64 (p < 0.0001;
n = 4,410), respectively. The within-subject correlation between the averaged potassium excretions of
the ﬁrst and the second examinations (separated by a median of 4.3 years; IQR 4.0–4.8 years) was
r = 0.49 (p < 0.0001; n = 4,429). Incident hypertension cases were diagnosed according to ofﬁce blood
pressure measurements and medication history. During a median follow-up of 7.6 years (IQR
5.0–9.3 years), 1,172 subjects developed hypertension. The lowest sex-speciﬁc tertile of potassium
excretion (men: < 68 mmol/24 h; women: < 58 mmol/24 h) had an increased risk of hypertension after
multivariable adjustment (hazard ratio (HR) = 1.20; 95% CI = 1.05–1.37), compared with the upper
two tertiles combined (pnon-linearity = 0.008). A multivariable-adjusted spline curve indicated a non-linear
inverse association of urinary potassium excretion with risk of hypertension. A higher risk of
hypertension was found with potassium excretion levels lower than 70 mmol/24 h, corresponding to a
potassium intake of 3,500 mg (90 mmol)/day.
Three prospective cohort studies in adults have investigated the association between potassium
intake, estimated through dietary assessment and subsequent blood pressure levels and/or
hypertension incidence.
Ford and Cooper (1991) analysed data from the US National Health and Nutrition Examination
Survey (NHANES) Epidemiologic Follow-up study (1971–1984). Dietary intake of potassium at baseline
was estimated through a 24-h recall dietary questionnaire (mean = 2,145 mg/day). The average SBP
and DBP data from two readings taken at the follow-up examination (mean follow-up 10 years) were
used to determine hypertensive status in a total of 5,411 white and black men and women free from
hypertension at baseline, and with complete dietary data available for analysis. Dietary potassium
intake at baseline was not associated with the incidence of hypertension (1,438 cases) in multivariate
analysis, when adjusting for age and energy intake. The Panel notes the methodological limitation of a
single 24-h dietary recall in assessing usual potassium intake of individuals.
A large prospective study involved 30,681 predominantly white US male health professionals,
40–75 years old, without diagnosed hypertension at baseline (Ascherio et al., 1992). Potassium intake at
baseline was measured by a semiquantitative FFQ (validated with 2 weeks of dietary records; correlation
for potassium = 0.65). The lowest category of potassium intake was < 2,400 mg (61 mmol)/day and
the highest category of potassium intake was ≥ 3,600 mg (92 mmol)/day. In this cohort, 1,248 men
self-reported a diagnosis of hypertension during the 4 years of follow-up. No associations were observed
between potassium intake and blood pressure levels at baseline and at the end of follow-up, or blood
pressure changes during the follow-up, when calcium, magnesium and dietary ﬁbre were considered in
the model, except for DBP level at baseline. No association was found in multivariate analysis between
potassium intake and risk of hypertension, after adjustment for potential dietary confounders (calcium,
magnesium and dietary ﬁbre) in addition to age, BMI and alcohol intake.
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Another large prospective study involved 41,541 predominantly white US female nurses, aged
38–63 years, without hypertension at baseline (Ascherio et al., 1996) updating a previous report in
the same cohort (Witteman et al., 1989). Potassium intake at baseline was measured through a
semi-quantitative FFQ (validated from 2 weeks of dietary records; correlation for potassium = 0.61).
The lowest of ﬁve categories of potassium intake was < 2,000 mg (51 mmol)/day and the highest
potassium intake category was ≥ 3,200 mg (82 mmol)/day. A total of 2,526 women reported to have
had a diagnosis of hypertension during the 4 years of follow-up. Using a multivariate analysis, no
association was found between potassium intake and the risk of hypertension, across the various
categories of daily potassium intake (< 2,000, 2,000–2,390, 2,400–2,790, 2,800–3,190, ≥ 3,200 mg),
adjusting for calcium, magnesium and dietary ﬁbre intake in addition to age, BMI and alcohol
consumption. Among women who did not report being diagnosed with hypertension, no associations
were observed between potassium intake and subsequent (after 2- or 4-year follow-up) self-reported
blood pressure levels, when calcium, magnesium and dietary ﬁbre were considered in a multivariate
regression model.
The Panel is aware of the inherent limitations in observational studies in relation to exposure
misclassiﬁcation (particularly for studies based on dietary questionnaires) or unmeasured confounding.
Overall, the Panel notes that the study by Kieneker et al. (2014), which used a multiple assessment of
24-h urinary potassium excretion and which was carried out in a European population, provides
evidence for an inverse association between potassium intake and risk of hypertension. In this study,
an increased risk of hypertension was observed in the lowest tertile of potassium excretion (men:
< 68 mmol/24 h; women: < 58 mmol/24 h). A spline regression analysis indicated a higher risk of
hypertension with urinary potassium excretion lower than 70 mmol/24 h, corresponding to a
potassium intake of 3,500 mg (90 mmol)/day.
Data in children
The relationship between potassium intake and blood pressure levels has also been studied in
children.
The WHO (2012c) carried out a meta-analysis of three intervention studies conducted in children. It
included a RCT in African-American boys and girls aged 13–15 years without hypertension (Wilson
et al., 1996), a RCT in individuals averaging 13 years of age and whose blood pressure was
> 109 mmHg for boys and > 108 mmHg for girls (Sinaiko et al., 1993) and one non-randomised trial in
normotensive boys and girls aged 11–14 years (Miller et al., 1987). The interventions consisted of
3 weeks with a high potassium (80 mmol/day; n = 20) vs usual diet (n = 20) (Wilson et al., 1996),
3 years with potassium supplementation (1 mmol/kg body weight per day; n = 71) vs placebo
(n = 69) (Sinaiko et al., 1993) and 4 weeks with potassium supplementation (36.2  12.8 mmol/day
for girls and 45.0  17.4 mmol/day for boys; n = 38) (Miller et al., 1987), respectively. Children were
characterised by background dietary potassium intakes in the order of 2,000 mg (51 mmol)/day
(Wilson et al., 1996), 2,800 mg (72 mmol)/day (Sinaiko et al., 1993) and 1,900 mg (49 mmol)/day
(Miller et al., 1987), as estimated through urinary potassium excretion. When pooling the estimates,
there was no effect of potassium supplementation on blood pressure levels (0.28 mmHg (95%
CI = 1.05–0.49) for resting SBP and 0.92 mmHg (2.00–0.20) for resting DBP).
In another case crossover RCT in 24 normotensive blacks and whites (aged 14.1  1.6 and
15.4  2.1 years, respectively), who received 40 mmol/day potassium supplement or a placebo for
7 days and then the alternate treatment, no effect of the potassium supplementation was found on
blood pressure levels (Pratt et al., 1997).
Three observational cohort studies on potassium intake and subsequent blood pressure levels have
been carried out in children.
The ﬁrst study by Geleijnse et al. (1990) assessed urinary potassium excretion in 233 Dutch
children (mean ( SD) age: 13.2 ( 2.7) years; range 5–17 years), who were followed for an average
of 7 years. Average potassium excretion during the follow-up was determined on the basis of six or
more annual overnight urine samples. During the study period, age showed no independent
association with estimated potassium intake. Ofﬁce blood pressure (average of two readings) was
assessed yearly. The subjects in the upper urinary potassium tertile (≥ 47.8 mmol/day), compared with
those in the lowest tertile (≤ 37.7 mmol/day), had a lower increase in SBP during an average follow-up
of 7 years (1.4 vs 2.4 mmHg, p = 0.007), while no association was found for DBP.
Brion et al. (2008) investigated the association between potassium intake in infancy (1-day diary at
4 months and 3-day diary at 8 months of age, including breastfeeding) and ofﬁce blood pressure
(average of two readings) at 7 years in children of the Avon Longitudinal Study of Parents and
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Children. In age- and sex-adjusted models, higher potassium intake at 4 months of age (n = 533) was
associated with higher SBP at follow-up (mean difference per 1 SD potassium = 0.89 mmHg; 95%
CI = 0.09–1.69, p = 0.03). No association was found with potassium intake at 8 months (n = 710;
mean difference = 0.12 mmHg/SD; 95% CI = 0.59–0.83; p = 0.7).
Buendia et al. (2015) assessed the association between potassium intake and blood pressure in a
US cohort study including 2,185 black and white girls initially aged 9–10 years and who were followed
up for 10 years. Potassium intake was estimated through 3-day diet records in eight of the 10 study
years and blood pressure as the average of two readings taken every year. Potassium intake was
inversely associated with the magnitude of blood pressure change throughout adolescence (p < 0.001
for SBP and DBP) and at the end of follow-up (p = 0.02 for SDP and p = 0.05 for DBP). In the
multivariate analysis adjusting for the largest number of potential confounders and using the
potassium residuals method, there was an inverse association of potassium intake with SBP in black
and with DBP in white subjects, with lower blood pressure values in the highest daily potassium intake
category (≥ 2,400 mg (61 mmol)/day).
The Panel notes that two prospective observational studies suggest that a ‘higher’ potassium intake
is associated with a reduction in the age-related increase in blood pressure. A limited number of
intervention studies with total potassium intake between 1,700 and 5,100 mg (43 and 130 mmol)/day,
and lasting 1 week to 3 years were carried out in children with baseline potassium intakes between
1,900 and 2,800 mg (49–72 mmol)/day. These studies did not show an effect of potassium
supplementation on blood pressure levels. The Panel notes the small sample size of these studies and
considers that available evidence is limited and cannot be used for the setting of DRVs for potassium
for children.
Factors affecting the relationship between potassium intake and blood pressure
(a) Sodium intake
In their meta-analysis, Aburto et al. (2013) conducted subgroup analyses according to levels of
sodium intake, as assessed through baseline urinary sodium excretion (Section 5.6.1.1). The largest
blood pressure-lowering effect of potassium was associated with the highest category of sodium intake
(greater than 4 g/day) compared to the lower categories (< 2 g/day and 2–4 g/day). The summary
estimates for SBP changes in the respective categories were 6.91 mmHg (95% CI = 11.53 to
2.29), 1.97 mmHg (95% CI = 3.41 to 0.52) and 2.00 mmHg (95% CI = 11.70–7.70), while
summary estimates for DBP changes were 2.87 mmHg (95% CI = 6.96–1.22), 1.96 mmHg
(95% CI = 3.16 to 0.76) and 0.00 mmHg (95% CI = 6.12–6.12). When the meta-analysis
was restricted to studies on individuals with hypertension, the systolic blood pressure was further
reduced in those studies where the baseline sodium intake was 2–4 g/day (4.07 mmHg;
95% CI = 5.76 to 2.37).
The Panel notes that these data indicate that the blood pressure-lowering effect of potassium is
observed in subjects consuming 2–4 g/day of sodium and is greater in subjects consuming more than
4 g/day of sodium, compared with lower levels of sodium intake.
(b) Sodium-to-potassium intake ratio
Attention has also been paid to the possibility that the sodium-to-potassium intake ratio, rather
than potassium and sodium intakes independently, may be related to hypertension or generally blood
pressure outcomes (Perez and Chang, 2014), or that such ratio may independently inﬂuence blood
pressure besides potassium (or sodium) intake itself (Binia et al., 2015).
In a systematic review by Perez and Chang (2014), evidence from RCTs carried out in hypertensive
subjects suggests that the sodium-to-potassium ratio is more strongly associated with blood pressure
outcomes than either sodium or potassium alone. This was supported by seven out of 10 pertinent
studies. There was methodological heterogeneity across the seven studies, in particular with respect to
the sodium and potassium intakes. All studies except one included in this meta-analysis estimated the
sodium-to-potassium intake ratio based 24-h urinary excretion collections. The methodological quality
of studies which provided support for a greater hypotensive effect of low sodium combined with high
potassium intakes compared to low sodium or high potassium alone (seven studies including four large
RCTs that followed subjects for at least 4 weeks) was generally stronger than that characterising the
studies that found no effect (three studies, with small study sizes or which used dietary intervention as
ancillary treatment). RCTs in normotensive subjects are scarce. A number of observational studies (one
prospective cohort and 23 cross-sectional studies) were also included in the review. The prospective
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cohort and the majority of the cross-sectional studies reported that the sodium-to-potassium ratio was
more strongly associated with hypertension and/or systolic and diastolic blood pressure levels than
either sodium or potassium alone. In two prospective cohort studies not included in this systematic
review, no association was found between the sodium-to-potassium excretion ratio and the risk of
incident hypertension after multivariate adjustment (Chien et al., 2008; Kieneker et al., 2014).
In their meta-regression analyses of 11 RCTs which assessed the effect of potassium intake on
blood pressure levels in normotensive (one study) and hypertensive subjects (10 studies), Binia et al.
(2015) found that the addition of the sodium-to-potassium excretion ratio in the model better
explained the effect of potassium supplementation in reducing SBP.
(c) Ethnic and genetic factors
Ethnic factors have been associated with differential blood pressure response to potassium in a few
observational studies (Liu et al., 2001; Stamler et al., 2013; Bartley et al., 2014), while evidence from
intervention studies is limited (Whelton et al., 1995).
A few studies have investigated the potential ability of some single nucleotide polymorphisms
(SNPs) to modify the blood pressure response to modiﬁcations in potassium intake (generally
associated with dietary sodium manipulations). In Chinese populations, some SNPs have been found to
modify such relation, including common genetic variants of the adiponectin gene (Chu et al., 2016), of
nuclear receptor subfamily 3, group C, member 2, angiotensin II type 1 receptor, hydroxysteroid
(11-b) dehydrogenase 1, and hydroxysteroid (11-b) dehydrogenase 2 genes (He et al., 2011) and
endothelin 1 (Montasser et al., 2010). A cross-sectional report from the large EPIC-Norfolk study has
shown that the association between urinary sodium-to-potassium ratio and blood pressure was
modiﬁed by the SNP rs17238540 in the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene
(Freitas et al., 2009). The Panel notes that the clinical signiﬁcance and the size of the effects of
possible interactions between genetic characteristics and blood pressure response to potassium intake
are not well deﬁned. Data in European and Western populations are limited.
(d) Conclusion
The Panel notes that most data available to date come from studies conducted in adult populations.
The Panel considers that the inﬂuence of sodium intake, sodium-to-potassium intake ratio, salt
sensitivity, ethnic and genetic factors on the effect of potassium intake on blood pressure needs to be
further investigated. Currently available evidence cannot be used for the setting of DRVs for
potassium.
Overall conclusion on potassium and blood pressure
The Panel considers that there is evidence from RCTs lasting from 4 weeks to 3 years for a
beneﬁcial effect of potassium intake on blood pressure in subjects classiﬁed as hypertensive (with or
without medication), but not in subjects classiﬁed as normotensive. In the analysis from Aburto et al.
(2013), which combined studies in hypertensive and normotensive people, the largest reduction in SBP
and DBP was found in the subgroup characterised by an ‘achieved’ potassium intake of
3,500–4,700 mg (90–120 mmol)/day, compared with lower and higher amounts. The Panel notes that
the only observational prospective cohort study which assessed potassium intake through potassium
excretion based on multiple 24-h urine collections and was carried out in a European adult population
of normotensive people, with a follow-up of 7.6 years, reported an inverse association between
potassium intake and hypertension incidence, with an increased risk observed for potassium intake
below 3,500 mg (90 mmol)/day (Kieneker et al., 2014).
5.6.1.2. Stroke
Stroke is one of the most common causes of morbidity and mortality in the European population
(Townsend et al., 2016).
A number of prospective cohort studies have investigated the association between potassium intake
and risk of stroke, which have been considered in several systematic reviews and meta-analyses
(Larsson et al., 2011a; WHO, 2012d; Aburto et al., 2013; D’Elia et al., 2014; Adebamowo et al.,
2015b; Vinceti et al., 2016) (Appendix H). All these analyses report a lower risk of stroke in the
highest category of potassium intake compared to the lowest (pooled relative risks (RRs) for models
adjusting for the highest number of variables between 0.76 (95% CI = 0.66–0.88) and
0.91 (95% CI = 0.88–0.94)).
Dietary reference values for potassium
www.efsa.europa.eu/efsajournal 28 EFSA Journal 2016;14(10):4592
Among these publications, only two report on dose–response analyses (Larsson et al., 2011a;
Vinceti et al., 2016).
Larsson et al. (2011a) conducted a dose–response meta-analysis using a restricted cubic spline
analysis. Data from eight prospective cohort studies (Appendix H), which reported RRs and 95% CIs
for at least three quantitative categories of potassium intake, were used in the model. The lowest
category of potassium intake (mean = 1,053 mg/day) was used as reference for the estimation of RRs.
The analysis showed a linear decrease in the risk of total stroke with increasing potassium intake up to
around 3,500 mg/day. Above this value, the inverse relationship was weaker and more uncertain
(wider conﬁdence intervals).
A more recent systematic review and dose–response meta-analysis included all studies considered
by Larsson et al. (2011a) plus those which became available thereafter (Vinceti et al., 2016)
(Appendix H). A total of 16 prospective cohort studies which investigated stroke incidence or stroke
mortality and assessed potassium intake through dietary questionnaires or urinary potassium excretion
were included (639,440 individuals, 19,522 stroke events). Eight studies assessed potassium intake
through food frequency questionnaires, four used structured dietary recall administered by a dietician,
two measured urinary potassium excretion with a single morning fasting urine sample, one measured
urinary potassium excretion with multiple 24-h urine collections and one study used both a food
frequency questionnaire and an overnight urine collection. The latter were included in the dose–
response analysis by applying a conversion factor of 1.3 to calculate dietary potassium intake from
24-h urinary potassium excretion. Six studies were conducted in the USA, ﬁve in Europe, three in Asia
and two studies recruited subjects from several countries. Median follow-up ranged from 3.7 to
25.8 years and was > 10 years in 12 studies. Ten studies reported a follow-up equal or higher than
95% of the baseline cohort. All studies controlled for age and all but two adjusted for smoking status,
while seven and ﬁve studies, respectively, also adjusted for history of hypertension or blood pressure
in one regression model. BMI, obesity, physical activity, total energy intake, serum cholesterol, and
intake of cholesterol, saturated fat and alcohol were other covariates generally considered in the
cohort studies. Median study quality was reported to be seven out of nine on the Newcastle-Ottawa
scale (range 4–9). There was no evidence of publication bias.
A pooled dose–response curve of RRs of stroke according to potassium intake was computed
using a restricted cubic spline analysis. An inverse relationship between potassium intake and risk of
stroke was observed up to around 90 mmol/day (3,500 mg/day), where the RR was 0.78
(95% CI = 0.70–0.86). Above this value, the dose–response curve ﬂattened and statistical imprecision
of the estimates increased. Several sensitivity analyses were conducted (e.g. after excluding studies
using urinary potassium to estimate intakes, removing studies which reported fatal stroke only, or
considering models which did not include blood pressure or hypertensive status as covariates), and did
not affect the nature of the association.
Conclusion
The Panel is aware of the inherent limitations in observational studies in relation to exposure
misclassiﬁcation (particularly for studies based on dietary questionnaires) or residual confounding. The
Panel notes that there is consistent evidence from prospective cohort studies for an inverse
relationship between potassium intake and risk of stroke. The Panel considers that there is a linear
decrease in the risk of total stroke with increasing potassium intake up to around 3,500 mg
(90 mmol)/day. Above this value, the risk of stroke does not appear to decrease further.
5.6.1.3. Coronary heart disease and overall cardiovascular disease
Seven observational prospective studies have investigated the association between potassium
intake and the risk of coronary heart disease or myocardial infarction (incidence or mortality). Five
studies measured urinary potassium excretion as a surrogate for potassium intake (Tunstall-Pedoe
et al., 1997; Geleijnse et al., 2007; O’Donnell et al., 2011, 2014; Kieneker et al., 2016) and two studies
estimated potassium intake through dietary questionnaires (Bazzano et al., 2001; Umesawa et al.,
2008). When comparing the highest to the lowest categories of potassium intake or excretion, four
studies reported inverse associations, two studies found positive associations, and one study found no
association between potassium intake and the risk of coronary heart disease or myocardial infarction.
There was substantial uncertainty associated with all risk estimates. The Panel considers that, overall,
these studies provided unclear and inconsistent evidence for an association between potassium intake
and coronary heart disease risk.
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A number of cohort studies also investigated the relationship between potassium intake and overall
cardiovascular disease (Geleijnse et al., 2007; Umesawa et al., 2008; Cook et al., 2009; O’Donnell
et al., 2011, 2014; Kieneker et al., 2016). A meta-analysis of the four studies published until 2013
yielded a summary RR of 0.88 (95% CI = 0.70–1.10; I2 = 69%) (Aburto et al., 2013). However, the
Panel notes that different deﬁnitions of ‘overall cardiovascular disease’ were applied in these studies,
covering heterogeneous endpoints (i.e. stroke and coronary disease were included in all cases, plus
different additional cardiovascular outcomes), thus hampering comparisons between studies and data
interpretation.
The Panel concludes that the results of these studies do not yield additional evidence that could
inform the setting of DRVs for potassium.
5.6.1.4. Conclusion on cardiovascular disease-related outcomes
The Panel notes the strengths and limitations of the evidence on the relationship between
potassium intake and cardiovascular outcomes and considers that there is evidence that a potassium
intake of 3,500 mg (90 mmol)/day has beneﬁcial effects on blood pressure in adults. Furthermore,
there is consistent evidence that potassium intake below 3,500 mg (90 mmol)/day is associated with a
higher risk of stroke. Results on the association between potassium intake and coronary heart disease
are unclear and inconsistent.
Overall, the Panel considers that the evidence on the relationship between potassium intake and
blood pressure and stroke can be used for setting DRVs for potassium for adults.
5.6.2. Diabetes mellitus type 2
A few prospective cohort studies have investigated the association between potassium intake and
risk of metabolic disease, in particular, diabetes mellitus type 2.
No association was found between baseline 24-h urinary potassium excretion and risk of type 2 diabetes
over 18 years follow-up in a cohort of 1,935 Finnish individuals aged 35–64 years (Hu et al., 2005).
Colditz et al. (1992) found an inverse association between dietary potassium intake (assessed with
a semiquantitative FFQ) and the risk of type 2 diabetes in a 6-year prospective cohort of non-obese
registered nurses in the USA (RR in Q1 vs Q5, 0.62; X trend 2.65 (p = 0.008)). In two prospective
studies carried out in the USA, no association was found between dietary potassium intake (assessed
by FFQ) and risk of incident diabetes in a cohort of 1,475 adults aged 45–65 years (9 years follow-up)
and in a cohort of 4,754 subjects aged ≥ 65 years (median follow-up of 12 years), after adjusting for
potential confounders (Chatterjee et al., 2010, 2015).
In another cohort of US adults aged 18–30 years, Chatterjee et al. (2012) considered 24-h urinary
potassium excretion as well as dietary potassium intake estimated through a quantitative FFQ. When
using urinary potassium (n = 1,066), the risk of incident type 2 diabetes was higher in individuals in
the lowest quintile of urinary potassium (< 35.3 mmol/24 h) compared to individuals in the highest
quintile (≥ 73.2 mmol/24 h) (HR = 2.45; 95% CI = 1.08–5.59; p for trend = 0.04), after adjustment
for potential confounders. No dose–response relationship emerged. When using dietary potassium
intake (n = 4,754), African Americans but not whites had a higher risk of developing type 2 diabetes in
the lowest quintiles of dietary potassium intake compared with the highest quintile (≥ 1,614 mg/
1,000 kcal per day); no dose–response relationship was evident.
The Panel considers that data from prospective studies investigating a relationship between urinary
potassium excretion or dietary potassium intake and risk of type 2 diabetes are limited and conﬂicting.
The Panel concludes that these data cannot be used to derive DRVs for potassium.
5.6.3. Bone health
A few intervention studies have assessed the effect of potassium supplementation on bone mineral
density (BMD). In a RCT where 276 post-menopausal women received 2,164 mg (55.5 mmol) or
6,493 mg (166.5 mmol) potassium per day as potassium citrate or a placebo for 2 years (mean
potassium intake at baseline: 3,200–3,500 mg/day across the groups), mean spine and hip BMD losses
in the placebo group did not differ from those in the treatment groups (Macdonald et al., 2008).
Frassetto et al. (2012) investigated a possible inﬂuence of salt sensitivity on bone response to
potassium alkali supplements by retrospectively analysing a subset of data from the trial of (Macdonald
et al., 2008) (70 out of 276 subjects) and a data set from a previous trial on 196 post-menopausal
women who received daily doses of 1,200, 2,300 or 3,500 mg (30, 60 or 90 mmol) potassium as
potassium bicarbonate or a placebo for 2 years (Frassetto et al., 2005). No effect of dietary alkali
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treatment on BMD was found for either study subgroup, nor did adjustment for the possible calcium-
or potassium-lowering effects on blood pressure alter these results. Jehle et al. (2013) conducted a
RCT on 201 older healthy adults who received either 7,020 mg (180 mmol) potassium/day as
potassium citrate or placebo, along with calcium (500 mg/day) and vitamin D3 (10 lg/day), for
2 years. Mean ( SD) urinary potassium excretion at baseline was 74  19 mmol/24 h and
73  22 mmol/day in the placebo and treatment groups, respectively. The net effect of potassium
citrate administration was an increase in BMD at the lumbar spine (primary endpoint) by 1.7%
(95% CI = 1.0–2.3). Positive effects of potassium citrate were also found for BMD at the femoral neck,
total hip and total body. Potassium citrate also had positive effects on volumetric BMD (measured by
CT scanning) for both dominant and non-dominant radius and tibia.
A number of studies investigated the effect of alkaline potassium salts on urinary calcium and acid
excretion and markers of bone turnover. In a meta-analysis, Lambert et al. (2015) found that
supplementation with alkaline potassium salts reduced calcium excretion and net acid excretion
compared to a placebo. Alkaline potassium salts lowered the bone resorption marker NTX (urinary
collagen type 1 cross-linked N-telopeptide), while no effect on markers of bone formation was
observed. Most studies used supplemental daily potassium doses ≥ 2,300 mg (60 mmol). Notably, in
studies which compared alkaline potassium salts with potassium chloride, a higher effect of the
alkaline salt on net acid excretion, as well as calcium excretion, was observed.
In a subset of 4,000 individuals (age at baseline: 59.7  9.6 years for men and 59.8  9.5 years
for women) from the EPIC–Norfolk cohort, no association was found between dietary intake of
potassium, assessed by a 7-day food diary, and risk of hip, spine, and wrist fractures at follow-up
stratiﬁed by sex and quintile of potassium dietary intake (1,502 fracture cases, mean follow-up
13.4 years) (Hayhoe et al., 2015).
The Panel notes the lack of evidence about an association between potassium intake and fracture
risk and the limited and inconsistent evidence for an effect of potassium supplementation on BMD. The
Panel also notes that most studies used alkaline potassium salts and cannot conclude on an
independent effect of potassium on bone health.
The Panel concludes that these data cannot be used to derive DRVs for potassium.
5.6.4. Kidney stones
In a prospective cohort study which involved 45,619 US men aged 40–75 years, potassium intake
(assessed with FFQ) was inversely related to the risk of kidney stones after 14 years of follow-up
(multivariate RR Q1 (< 2,914 mg (75 mmol)/day) vs Q5 (> 3,958 mg (101 mmol)/day) = 0.54;
95% CI = 0.42–0.68; p for trend < 0.001) (Taylor et al., 2004). In another cohort of 91,731 US
women aged 34–59 years participating in the NHS I (12 years follow-up), the multivariate RR among
women in the highest quintile (> 4,099 mg (105 mmol)/day) of potassium intake compared with those
in the lowest quintile (< 2,407 mg (626 mmol)/day) was 0.65 (95% CI = 0.51–0.84; p for trend
< 0.001) (Curhan et al., 1997). In a cohort of 27,001 Finnish male smokers aged 50–69 years followed
up for 5 years, no association was found between baseline potassium intake and the incidence of
kidney stones in the fully adjusted multivariate model (RR = 0.79; 95% CI = 0.52–1.19; ptrend = 0.34)
(Hirvonen et al., 1999). In that cohort, median potassium daily intakes in each quartile were 3,800 mg
(97 mmol), 4,600 mg (118 mmol), 5,100 mg (131 mmol) and 5,800 mg (149 mmol), respectively.
The use of potassium citrate, as well as other citrate salts, has been investigated for the management
of stone disease (Phillips et al., 2015). Because available RCTs used potassium in the form of alkaline
salts, an independent effect of potassium on stone formation or stone growth cannot be ascertained.
Potassium citrate is used in the treatment of hypocitraturia, which is one of the most common metabolic
abnormalities associated with calcium kidney stone formation (T€urk et al., 2015). Although the potassium
moiety has been proposed to have an independent effect on urinary citrate excretion (Jaipakdee et al.,
2004), RCTs found no effect of potassium chloride on urinary citrate excretion (Sakhaee et al., 1991;
Tosukhowong et al., 2002; Jaipakdee et al., 2004; Maalouf et al., 2011). Similarly, no independent effect
of potassium on urinary pH was found (Jaipakdee et al., 2004; Maalouf et al., 2011).
The Panel notes that there is some evidence for an association between low potassium intake
and the increased risk of kidney stones from prospective cohort studies. However, an independent
effect of potassium on kidney stones cannot be ascertained from available RCTs. Available RCTs
using potassium chloride do not support an independent effect of potassium on urinary citrate
excretion and pH.
The Panel concludes that these data cannot be used to derive DRVs for potassium.
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6. Data on which to base dietary reference values
The Panel decides to set DRVs for potassium on the basis of the relationships between potassium
intake and blood pressure and stroke (Section 5.6.1).
6.1. Adults
There is evidence that a potassium intake of 3,500 mg (90 mmol)/day has a beneﬁcial effect on
blood pressure in adults. Furthermore, there is consistent evidence that potassium intakes below
3,500 mg (90 mmol)/day are associated with a higher risk of stroke. Currently, available data do not
allow the determination of the distribution of individual requirements for potassium in relation to these
endpoints. The Panel considers that available data cannot be used to determine the AR for potassium
but can be used as a basis for deriving an adequate intake (AI).
The Panel considers that a potassium intake of 3,500 mg (90 mmol)/day can be considered
adequate for the adult population. The Panel sets an AI of 3,500 mg (90 mmol)/day for adult men and
women.
6.2. Infants and children
No data are available on which to base an average potassium requirement for infants and children.
The Panel proposes AIs extrapolated from the AI for adults: considering the distribution of potassium
in all the compartments of the body and the size of the rapidly exchangeable pool (Section 2.3.3),
isometric scaling was used, taking into account differences in reference body weight (isometric scaling)
and including a growth factor to take into account requirements for growth:
AIchild ¼ AIadultðbody weight of child=body weight of adultÞð1þ growth factorÞ:
The following growth factors have been applied: 0.57 for boys and girls aged 7–11 months, 0.25
for boys and girls aged 1–3 years, 0.06 for boys and girls aged 4–6 years, 0.13 for boys and girls aged
7–10 years, 0.11 for boys and 0.08 for girls aged 11–14 years, and 0.08 for boys and 0.03 for girls
aged 15–17 years (EFSA NDA Panel, 2014).
During childhood, there are differences in potassium body accretion rates between boys and girls,
which reﬂect their respective patterns of skeletal muscle gain (Sections 2.3.4 and 5.3). However, the
Panel considers that these differences are negligible relative to the overall potassium requirement. The
Panel decides to set AIs that apply to both boys and girls. The age categories proposed by the EFSA
NDA Panel (2010) are applied (Table 4).
6.3. Pregnancy
The Panel notes that there is a lack of data on potassium requirement in pregnancy, but considers
that the requirement for the daily accretion rate of potassium in fetal and maternal tissues can be met
Table 4: Reference body weights and adequate intakes (AIs) of potassium for children
Age Reference body weight (kg)(a) AI (mg/day)(b),(c)
7–11 months 8.6 750
1–3 years 11.9 800
4–6 years 19.0 1,100
7–10 years 28.7 1,800
11–14 years 44.6 2,700
15–17 years 60.3 3,500
(a): Rounded mean of median weight-for-age of boys and girls aged 24 months, according to the WHO Growth Standard (WHO
Multicentre Growth Reference Study Group, 2006), and aged 5, 8.5, 12.5 and 16 years, according to van Buuren et al.
(2012).
(b): Adequate intakes were derived from the unrounded AI for adults after adjustment on the basis of differences in reference
body weight and application of a growth factor, then rounded to the closest 50.
(c): Equivalent to: 19 mmol/day for infants 7–11 months, 20 mmol/day for children aged 1–3 years, 28 mmol/day for children
aged 4–6 years, 46 mmol/day for children aged 7–10 years, 69 mmol/day for children aged 11–14 years and 90 mmol/day
for children aged 15–17 years.
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by the adaptive changes which maintain potassium homeostasis during pregnancy (Section 5.4); thus,
the AI for pregnant women is set at 3,500 mg (90 mmol)/day, the same as for non-pregnant women.
6.4. Lactation
An average amount of potassium secreted in breast milk of 400 mg (10 mmol)/day was estimated
(Section 2.3.5.4). There are no data on adaptive changes in potassium metabolism during lactation,
but some evidence indicates that total body potassium content decreases in lactating women
(Section 5.5). Taking a conservative approach, the Panel proposes to increase the AI for lactating
women in order to compensate for the losses of potassium through breast milk.
There is no speciﬁc information on potassium absorption efﬁciency in lactating women. Considering
an absorption efﬁciency of 90% from usual diets based on data in non-lactating subjects
(Section 2.3.1), an additional potassium intake of 444 mg (11 mmol)/day was considered sufﬁcient to
replace these losses. Thus, an AI of 4,000 mg (102 mmol)/day is proposed for lactating women, after
rounding up to the closest 100.
Conclusions
The Panel concludes that there is insufﬁcient evidence to derive an AR and a PRI for potassium.
Evidence on the relationships between potassium intake and blood pressure and risk of stroke are
used to set an AI for adults (Table 5). It is considered unnecessary to give sex-speciﬁc values. The
Panel proposes that the adult AI also applies to pregnant women. For lactating women, an increase in
AI is proposed on the basis of the estimated loss of potassium secreted in breast milk. In infants over
6 months of age and in children, AIs are proposed based on extrapolation from the adult AI using
isometric scaling and body weights of the age groups and application of a growth factor.
Recommendations for research
The Panel recommends improving the knowledge of potassium metabolism and homeostasis, and
of its inter-relationship with the metabolism of sodium and chloride. This would, in turn, allow the
identiﬁcation of potential biomarkers for validation and use in population-based health studies.
The Panel recommends further studies on the relationship between potassium intake and
cardiovascular endpoints, in particular in relation to hypertension and stroke risk. Further investigation
into the mechanisms involved in the protective role of potassium against these conditions is needed.
The Panel recommends that the potential modiﬁcation of the effect of potassium intake on blood
pressure by sodium intake, sodium-to-potassium intake ratio, salt sensitivity, ethnic and genetic factors
be further investigated.
The Panel recommends further research on a potential ‘independent’ effect of potassium on bone
health.
The Panel also recommends generating evidence that can be used to assess the potassium
requirements of infants and children.
Table 5: Summary of dietary reference values for potassium
Age AI(a) (mg/day)
7–11 months 750
1–3 years 800
4–6 years 1,100
7–10 years 1,800
11–14 years 2,700
15–17 years 3,500
≥ 18 years 3,500
Pregnancy 3,500
Lactation 4,000
AI: Adequate intake.
(a): Equivalent to: 19 mmol/day for infants 7–11 months, 20 mmol/day for children aged 1–3 years, 28 mmol/day for children
aged 4–6 years, 46 mmol/day for children aged 7–10 years, 69 mmol/day for children aged 11–14 years, 90 mmol/day for
children aged 15–17 years, 90 mmol for adults, including pregnant women, and 102 mmol for lactating women.
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AI adequate intake
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ATP adenosine triphosphate
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BMI body mass index
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DBP diastolic blood pressure
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FSANZ Food Standards Australia New Zealand
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I2 heterogeneity index
ICP-AES inductively coupled plasma–atomic emission spectroscopy
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NDNS UK National Diet and Nutrient Survey
NHANES US National Health and Nutrition Examination Survey
NHS Nurses’ Health Study
NNR Nordic Nutrition Recommendations
NTX urinary collagen type 1 cross-linked N-telopeptide
NWSSP Nutrition and Wellbeing of Secondary School Pupils
PREVEND Prevention of Renal and Vascular End-Stage Disease study
PRI population reference intake
PURE Prospective Urban Rural Epidemiology study
RCT randomised controlled trial
RNI Recommended Nutrient Intake
RR Relative risk
SBP systolic blood pressure
SCF Scientiﬁc Committee for Food
SD standard deviation
SEM standard error of the mean
SM skeletal muscle
SNP single nucleotide polymorphism
TBK total body potassium
UL tolerable upper intake level
UNU United Nations University
VELS Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme von S€auglingen
und Kleinkindern f€ur die Absch€atzung eines akuten Toxizit€atsrisikos durch
R€uckst€ande von Pﬂanzenschutzmitteln
WHI Women’s Health Initiative study
WHO World Health Organization
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Appendix A – Potassium concentration in breast milk from mothers of term
infants in Western countries
Reference
Number of
women
(number of
samples)
Country
Stage of
lactation
Potassium concentration
(mg/L) Analytical
method
Mean  SD Median
Bauer and
Gerss (2011)
10 Germany 1–8 weeks 450  74 Absorption
spectrometry
and colorimetry
Bjorklund et al.
(2012)
60 (60) Sweden 2–3 weeks 633  40 636 (range:
549–729)
ICP-MS
Fly et al.
(1998)
14 (28) USA 2–8 months 459  24
(at rest)
445  15
(after exercise)
ICP-AES
Holt (1993) 4 (28) UK 5–16 weeks 594  86 Flame
photometry
Keenan et al.
(1982)
28 (40) USA 3.5–6 weeks
8.5–18 weeks
20–32 weeks
592  70
538  50
519  43
Flame
photometry
Parr et al.
(1991)
(71) Hungary 3 months 554 AAS
(29) Sweden 548
Wack et al.
(1997)
30 (140) USA 0–60 days
61–120 days
121–180 days
181–240 days
241–300 days
301–360 days
> 360 days
585  124
490  85
485  66
473  63
470  72
445  53
461  89
ICP-AES
Witczak and
Jarnuszewska
(2011)
(9) Poland 5–6 months 520 ICP-AES
Studies were identiﬁed by a comprehensive literature search for publications from October 2010 to January 2014 (LASER
Analytica, 2014) and additional searches of the literature before these dates. If studies did not report whether infants were born
at term or not, it was presumed that infants were born at term.
AAS: atomic absorption spectroscopy; ICP-AES: inductively coupled plasma atomic emission spectroscopy; ICP-MS: inductively
coupled plasma mass spectrometry.
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Appendix E – Minimum and maximum percentage contribution of different food
groups (FoodEx2 level1) to potassium intakes in males
Food groups
Age (years)
< 1 year
1 to
< 3 years
3 to
< 10 years
10 to
< 18 years
18 to
< 65 years
65 to
< 75 years
≥ 75 years
Additives, ﬂavours,
baking and processing
aids
< 1 < 1 0 < 1–1 < 1 < 1 0
Alcoholic beverages < 1 < 1 < 1 < 1–1 3–7 2–7 2–7
Animal and vegetable fats
and oils
< 1 < 1 < 1 < 1 < 1 < 1 < 1
Coffee, cocoa, tea and
infusions
< 1–2 < 1–5 1–8 2–6 5–13 5–14 4–12
Composite dishes < 1–4 < 1–7 < 1–7 < 1–10 < 1–13 < 1–12 < 1–12
Eggs and egg products < 1 < 1–1 < 1–1 < 1–1 < 1–1 < 1–1 < 1–1
Fish, seafood,
amphibians, reptiles and
invertebrates
< 1–1 < 1–4 < 1–4 < 1–4 1–4 2–5 2–5
Food products for young
population
20–54 3–16 < 1–1 < 1 < 1 – –
Fruit and fruit products 5–14 9–14 6–11 4–9 4–11 6–14 6–14
Fruit and vegetable juices
and nectars
< 1–2 1–8 4–10 4–10 1–6 1–5 1–3
Grains and grain-based
products
3–6 8–14 9–19 11–20 11–15 11–17 12–19
Human milk < 1–26 < 1–1 – – – – –
Legumes, nuts, oilseeds
and spices
< 1–2 1–3 1–4 1–4 1–4 1–4 1–3
Meat and meat products < 1–4 4–8 6–13 8–16 9–15 8–13 7–12
Milk and dairy products 7–18 25–34 17–36 13–30 9–19 8–18 10–14
Products for non-standard
diets, food imitates and
food supplements or
fortifying agents
< 1 0 < 1–1 < 1–1 < 1–2 < 1 < 1–1
Seasoning, sauces and
condiments
< 1–1 < 1–1 < 1–2 < 1–2 < 1–3 < 1–1 < 1–1
Starchy roots or tubers
and products thereof,
sugar plants
1–21 6–19 10–18 12–21 9–19 9–18 12–19
Sugar, confectionery and
water-based sweet
desserts
< 1 < 1–1 1–4 1–4 < 1–1 < 1–1 < 1–1
Vegetables and vegetable
products
1–15 5–10 7–16 7–19 5–24 5–24 6–22
Water and water-based
beverages
< 1 < 1–1 < 1–2 < 1–2 < 1–4 < 1–2 < 1–2
‘–’ means that there was no consumption event of the food group for the age and sex group considered, whereas ‘0’ means that there were
some consumption events, but that the food group does not contribute to potassium intake in the age and sex group considered.
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Appendix F – Minimum and maximum percentage contribution of different food
groups (FoodEx2 level1) to potassium intakes in females
Food groups
Age (years)
< 1 year
1 to
< 3 years
3 to
< 10 years
10 to
< 18 years
18 to
< 65 years
65 to
< 75 years
≥ 75 years
Additives, ﬂavours,
baking and processing
aids
< 1 0 0 < 1–1 < 1 < 1 0
Alcoholic beverages < 1 < 1 < 1 < 1 < 1–3 1–3 1–2
Animal and vegetable
fats and oils
< 1 < 1 < 1 < 1 < 1 < 1 < 1
Coffee, cocoa, tea and
infusions
< 1–15(a) < 1–5 1–8 2–6 4–15 4–17 4–12
Composite dishes < 1–2 < 1–7 < 1–7 < 1–10 < 1–14 < 1–12 < 1–14
Eggs and egg products < 1 < 1–1 < 1–1 < 1–1 < 1–1 < 1–1 < 1–1
Fish, seafood,
amphibians, reptiles and
invertebrates
0 < 1–6 < 1–3 < 1–4 1–4 1–5 1–5
Food products for
young population
19–57 3–16 < 1–1 < 1 < 1 – < 1
Fruit and fruit products 8–12 9–14 7–12 6–15 7–13 9–16 9–17
Fruit and vegetable
juices and nectars
< 1–2 1–7 3–10 3–10 2–6 1–4 2–4
Grains and grain-based
products
4–6 9–14 9–18 12–19 12–23 10–16 10–18
Human milk < 1–9 < 1–1 – – – – –
Legumes, nuts, oilseeds
and spices
< 1–2 1–3 1–4 1–3 2–4 1–3 1–2
Meat and meat products 1–4 4–7 5–14 7–14 8–12 7–11 6–11
Milk and dairy products 4–22 23–38 17–37 11–27 10–20 10–18 12–16
Products for non-
standard diets, food
imitates and food
supplements or
fortifying agents
< 1 < 1 0–1 < 1–1 < 1–2 < 1–1 < 1–1
Seasoning, sauces and
condiments
< 1–1 < 1–1 < 1–2 < 1–2 < 1–2 < 1–1 < 1–1
Starchy roots or tubers
and products thereof,
sugar plants
4–20 6–17 10–19 11–23 8–17 9–15 10–13
Sugar, confectionery
and water-based sweet
desserts
< 1–1 < 1–1 1–3 1–4 < 1–5 < 1–1 < 1–1
Vegetables and
vegetable products
4–17 6–12 8–16 8–20 7–24 7–24 7–22
Water and water-based
beverages
< 1–1 < 1–1 < 1–3 < 1–2 < 1–4 < 1–3 < 1–3
‘–’ means that there was no consumption event of the food group for the age and sex group considered, whereas ‘0’ means that there were
some consumption events, but that the food group does not contribute to potassium intake in the age and sex group considered.
(a): The value of 15% comes from the INRAN_SCAI_2005_06 survey (n girls < 1 year = 7) and originates from one subject who drank small
amounts of tea on each of the 3 days of the survey.
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Appendix G – Comparison between EFSA intake estimates and published
estimates from the same survey
Country Survey (age range) Reference
Percentage of published
intake(a)
Finland NWSSP (13–15 years) Hoppu et al. (2010) 102–103
FINDIET 2012 (25–74 years) Helldan et al. (2013) 95–97
France INCA2 (3–17 years) Afssa (2009) 92–102
Germany EsKiMo (6–11 years) Mensink et al. (2007) 105–112
VELS (< 1–4 years) Kersting and Clausen (2003) 97–105(b)
Ireland NANS (18–90 years) IUNA (2011) 101–107
Italy INRAN-SCAI (1 month–98 years) Sette et al. (2011) 95–109
Netherlands DNFCS 2007_2010 (7–69 years) van Rossum et al. (2011) 96–99
UK NDNS years 1–3 (3–94 years) Bates et al. (2012) 97–107
DNFCS: Dutch National Food Consumption Survey; EsKiMo: Ern€ahrungsstudie als KIGGS-Modul; FINDIET: the national dietary
survey of Finland; INCA: etude Individuelle Nationale des Consommations Alimentaires; INRAN-SCAI: Istituto Nazionale di Ricerca
per gli Alimenti e la Nutrizione - Studio sui Consumi Alimentari in Italia; NANS: National Adult Nutrition Survey; NWSSP: Nutrition
and Wellbeing of Secondary School Pupils; VELS: Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme von S€auglingen und
Kleinkindern f€ur die Absch€atzung eines akuten Toxizit€atsrisikos durch R€uckst€ande von Pﬂanzenschutzmitteln.
(a): Range over different age groups in a speciﬁc survey.
(b): For the VELS survey, the comparison refers to median values, as average potassium intake estimates were not available in
the literature.
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Appendix H – Meta-analyses of prospective cohort studies on potassium intake and risk of
total stroke
Individual studies Country
Larsson et al.
(2011a)
Aburto et al.
(2013), WHO
(2012d)
D’Elia et al.
(2014)
Adebamowo
et al. (2015b)
Vinceti et al.
(2016)
Khaw and Barrett-
Connor (1987)
USA x x x x x
Lee et al. (1988) Japan – – – – x
Ascherio et al.
(1998)
USA x x x x –(e)
Iso et al. (1999) USA x x x x –(f)
Bazzano et al.
(2001)
USA x x x x x
Green et al. (2002) USA x x x x x
Geleijnse et al.
(2007)(a)
Netherlands x x x x x
Larsson et al. (2008) Finland x x x x x
Umesawa et al.
(2008)
Japan x x x x x
Weng et al. (2008) Taiwan x x x x x
Larsson et al.
(2011b)
Sweden x – x x x
O’Donnell et al.
(2011)(a)
40 countries(b) – x x – x
Sluijs et al. (2014) Netherlands – – x x x
Adebamowo et al.
(2015a)
USA – – – x x
Adebamowo et al.
(2015b)
USA – – – – x
Seth et al. (2014) USA – – – – x
O’Donnell et al.
(2014)(a)
40 countries(b) – – – – x
Kieneker et al.
(2016)(a)
Netherlands – – – – x
Number of studies included 10 10 12 12 16
Pooled RR (95% CI)(c) 0.89 (0.83–0.96)
by 1,000 mg
increase of
potassium intake
(I2 = 50.8%(d))
0.76 (0.66–0.88)
for higher
potassium intake
compared to
lower potassium
intake (I2 = 62%)
0.80 (0.72–0.90)
for higher
potassium intake
compared to
lower potassium
intake (I2 = 47%);
0.90 (0.84–0.96)
by 1,000 mg
increase of
potassium intake
(I2 = 47%)
0.91 (0.88–0.94)
by 1,000 mg
increase of
potassium intake
(I2 not reported)
0.87 (0.80–0.94)
for higher
potassium intake
compared to lower
potassium intake
(I2 = 45.5%)
CI: conﬁdence interval; I2: heterogeneity index; RR: relative risk.
(a): Potassium intake estimated on the basis of urinary potassium excretion.
(b): Argentina, Australia, Austria, Belgium, Canada, China, the Czech Republic, Denmark, Finland, France, Germany, Greece, Hong King, Hungary, Ireland,
Italy, Malaysia, Mexico, the Netherland, New Zealand, Norway, the Philippines, Poland, Portugal, Russia, Singapore, Slovakia, South Africa, South Korea,
Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Arab Emirates, the United Kingdom, the USA.
(c): Calculated from study-speciﬁc RRs adjusted for the most number of covariates.
(d): In a sensitivity analysis, Khaw and Barrett-Connor (1987) was found to account for the observed heterogeneity. When that study was omitted, the pooled
RR was 0.91 (95% CI = 0.86–0.96) and between-study heterogeneity was I2 = 20.7%.
(e): Not included as more recent results for the same cohort were available (Adebamowo et al., 2015a).
(f): Not included as more recent results for the same cohort were available (Adebamowo et al., 2015b).
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